UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 10-K
| ☒ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| |
|
| |
For the fiscal year ended October 31, 2015 |
| |
|
| |
OR |
| |
|
| ☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission file number 000-53051
Advanced Biomedical Technologies Inc.
(Exact name of registrant as specified in its charter)
Nevada
(State or other jurisdiction of incorporation or organization)
Empire State Building
350 Fifth Ave, 59th Floor
New York, NY 10118
(Address of principal executive offices, including zip code.)
(718) 766-7898
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.00001 par value
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐
Indicate by check mark whether registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☒ NO ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “small reporting company” in Rule 12b-2 of the Exchange Act.
| |
Large accelerated filer |
☐ |
|
Accelerated filer |
☐ |
| |
|
|
|
|
|
| |
Non-accelerated filer |
☐ |
|
Smaller reporting company |
☒ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
There was no active public trading market as of the last business day of the Company’s year-end.
The aggregate market value of common stock held by non-affiliates of the registrant, computed by reference to the price at which the common equity was last sold being $0.14 on April 30, 2015 which is the last trading day of the second quarter, was approximately $2,648,300 as of April 30, 2015 (the last business day of the registrant’s most recently completed second quarter), assuming solely for the purpose of this calculation that all directors, officers and more than 10% stockholders of the registrant are affiliates. The determination of affiliate status for this purpose is not necessarily conclusive for any other purpose.
As of February 16, 2016, there are 66,874,850 shares of common stock outstanding.
TABLE OF CONTENTS
SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS
Investors are cautioned that certain statements contained in this document, as well as some statements in periodic press releases and some oral statements of Advanced Biomedical Technologies Inc. (“ABMT”) officials during presentations about ABMT, are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” or similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future ABMT actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements are based on current expectations and projections about future events and are subject to risks, uncertainties, and assumptions about ABMT, economic and market factors and the industries in which ABMT does business, among other things. These statements are not guaranties of future performance and we have no specific intention to update these statements.
Actual events and results may differ materially from those expressed or forecasted in forward-looking statements due to a number of factors. Although forward-looking statements in this Annual Report on Form 10-K reflect the good faith judgment of our management, forward-looking statements are inherently subject to known and unknown risks, business, economic and other risks and uncertainties that may cause actual results to be materially different from those discussed in the forward-looking statements, and Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K.
Organizational History
Advanced Biomedical Technologies, Inc. has one direct wholly owned subsidiary, Masterise Holdings Ltd., a limited liability company organized under the laws of British Virgin Islands (“Masterise”). Masterise, owns seventy percent (70%) of the issued and outstanding equity or voting interests in Shenzhen Changhua, a company formed under the laws of the People’s Republic of China. (ABMT, Masterise, and Shenzhen Changhua are collectively referred to throughout this document as “We, “Us,” “Our” (and similar pronouns), “ABMT” and the “Company”).
We were incorporated in the State of Nevada on September 12, 2006. We maintain our statutory registered agent’s office at The Corporation Trust Company of Nevada, 311 S Division Street, Carson City, Nevada 89703, and our business office is located at 350 Fifth Avenue, 59th Floor, New York, NY 10118. We have not been subject to any bankruptcy, receivership, or similar proceeding, or any material reclassification or consolidation.
Our primary business is carried out by Masterise through Shenzhen Changhua, as set forth in the following diagram:
Shenzhen Changhua does not have any subsidiary.
Organizational History of Masterise and Shenzhen Changhua
Masterise is a wholly owned subsidiary of Advanced Biomedical Technologies, Inc.
Masterise is a limited liability company which was organized under the laws of British Virgin Islands (“BVI”) on May 31, 2007, and owns 70% of the capital stock of Shenzhen Changhua.
Shenzhen Changhua is a limited liability company which was organized under the laws of PRC on September 25, 2002.
Since their founding, Shenzhen Changhua has been involved in the development of self-reinforced, absorbable degradable screws, rods and binding wires for fixation on human fractured bones. The Company is currently involved in conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending approval of its products by the China Food and Drug Administration (“CFDA”), formally the State Food and Drug Administration (“SFDA”) of the PRC.
Primary Products
Our primary products include Absorbable PA Osteosynthesis Devices made of a proprietary polyamide material. These advanced materials are used in surgical screws, binding wires, rods and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, and reconstructive dental procedures. Our devices are Self-Reinforced, Bio-absorbable, Brady-degradable internal fixation devices. At this time, ABMT is the sole patent holder of PA technologies in China, as well as the only company currently engaged in clinical trials and marketing submission for PA devices in the PRC. Our PA Screws have completed clinical trials and are pending approval by the China Food and Drug Administration of China (“CFDA”); and our PA Binding Wires are under clinical trials; and our PA Mini-Screws are under animal test.
Product Characteristics:
The theory of Brady-degradable PA absorbable material is based on water dissolution, that is, the material is broken down by body fluids in a predictable and carefully engineered fashion. As a bone fracture heals, the supporting implant is designed to degrade from the outer to the inner layers, inducing new bone generation in the gap left by the degrading material. Eventually, new bone is formed to occupy all of the space left by the degraded implant.
Brady-degradable PA absorbable materials consist of enhanced fiber and high molecular polymers. It has high tensile, bending, and shear strengths, and is particularly suitable for patients with severe conditions, high tensile, bending, and shear strengths, and is particularly suitable for patients with severe conditions, such as fractures with light osteoporosis, severe soft tissue injury or bad blood supply, and so forth. This innovative material provides several benefits:
1. Reduces costs on all patient medical care,
2. Helps avoid the necessity for secondary surgery,
3. Enhances the performance of components constructed from these materials,
4. Improves the biological activity of components employing these materials,
5. Effectively controls the degeneration speed of the temporary support component.
The Company has developed six proprietary re-absorbable polymer fixation implant product lines, including screws, pins, tacks, rods and binding wires, which provide an alternative to metal implants and overcome the limitations of first generation re-absorbable fixation devices. The Company’s product range will ultimately cover the full gamut of components featuring self-reinforced, re-absorbable, biodegradable PA macromolecule polymer materials for implantation, including human orthopedic and dental applications, as well as veterinary applications.
Industry Development
The fracture fixation industry has developed through three generations of materials science:
The first generation internal-fracture fixation material:
The first generation internal-fracture-fixer components are usually made of stainless steel, titanium and alloy. Due to their high intensity, low costs and easy machining character, these components have achieved huge success in fracture treatment and remain the most widely used internal-fracture-fixer material. However, their prominent flaws are the huge difference between metal’s elasticity co-efficient, easily causing second-time bone fracture. The metallic ion can also cause tissue inflammation, and the need of a secondary surgery to have them taken out. These flaws stimulated the development of the degradable macromolecule material.
The second generation fracture fixation material:
The second generation bone-fracture-fixed components are made of degradable macromolecule material, such as PLLA, PGA and PDS, etc. The disadvantage of these components is rapid self-degeneration in early stages after the initial implant. For example, the strength of SR-PLLA decreases to 10-20Mpa after 4 weeks of implantation. Therefore, the second generation bone-fracture-fixed components can be only used to treat substantial spongiosa bone fractures.
The third generation fracture fixation material:
The third generation fracture fixation material, biodegradable fracture fixation components are currently under research by developed countries. There are many technical challenges to research in the third generation fracture fixation material field; for example, the materials must have a high degree of bio-compatibility and mechanical compatibility. They also must be of high biological activity, self-absorbable, and degeneration controllable.
Product Development
After careful deliberation, we selected the biodegradable screw as our first product to market. In order to replace the widely-used metal components, the new materials must meet multiple bio-consistency and mechanical-consistency requirements. Furthermore, they must also exhibit specific properties with respect to bio-activities, degradability, and controllable degradation speed. Although many macromolecule materials are degradable inside human body, relatively few provide the physical characters required for fracture fixation.
Development began with selection of macromolecule materials that exhibited the desired physical characters, leading, ultimately, to our selection of polyamide. In order to achieve the desired mechanical performance and degrading speed, various chemical and physical techniques were employed to modify the bio-degradable polyamide so as to synthesize the required new bio-degradable material. This phase of our research also entailed the selection of monomer class, polymerization conditions, the mensuration of polymer molecular weight, hydrophile capability, crystal capability, the mensuration and controlled degrading speed of the polymer, the mensuration and control of the mechanical performance of the polymer, and numerous other critical considerations.
Our next challenge was to identify a suitable bio-active inorganic material, and to optimize the compound and associated production conditions. It was critical that we could predict and control the bio-activities of the implanted fixture material, and to this end we used high grade and mature phosphate type bio-active materials, taking into account the preparation characteristics of the compound material, and the surface character requirements of the finished products. We also improved current technical parameters by modifying the surface character, thereby achieving critical control over the desired grain size and surface activities.
The third technological hurdle involved the actual preparation and utilization of the engineered compound in conjunction with a bio-active material. Hydronium bombardment of the surface, with spread and cover techniques, was employed during this critical step in the process. This had the effect of creating a well-knit bio-active membrane on the degradable polymer’s surface, and embedding a bio-active core inside the degradable polymer stick, so as to form the bio-active degradable compound material.
The final step entailed strengthening and shaping the processed compound by using directional extrusion and molding. Degradable acantha inoculators, fixation screws, orthopedics stuffing, enlace strings, and anti-conglutination membrane can all be manufactured, as needed, using this same technique.
Our company has studied and researched Polyamide, changing its chemical and physical properties to meet the above requirements. As a result of our research we have:
| 1. |
Increased mechanical strength to 170Mpa. |
| 2. |
Increased biological activities to accelerate bone cell substitution. |
| 3. |
Extended the degeneration period during the implant. While the PA is degenerating layer by layer, the bone cells grow and take its place. |
Product Analysis
Our Company is researching and currently developing the capability of manufacturing several different kinds of human implant products including Artificial Lumbar Disc, Mini-Screws, Suture Anchors, reconstructive dental devices and other PA products. Currently the company has two production lines certified by the GMP regulations.
Our Company is constantly analyzing the market needs to develop suitable products. One of the company’s products is currently pending CFDA approval and two products are under clinical tests.
Overview of PA Devices and Market in the US, China and Worldwide
Fractures are among the most common orthopaedic problems. There are estimated 1.5 million fracture cases each year in the United States alone (Riggs and Melton 1995), and the average citizen in a developed country can expect to sustain two fractures over the course of their lifetime. Fractures occur at an annual rate of 2.4 per 100 population. Men are more likely to experience fractures (2.8 per 100 population) than women (2.0 per 100). In 1998, over 10.7 million fractures were seen by physicians in office-based practice (this included visits for follow-up care). Of these, approximately 8.6 million visits for fracture care (79.6%) were made to orthopaedic surgeons. When a fracture was referred to another physician, approximately 90.6% were referred to orthopaedic surgeons. (Data Source: National Ambulatory Medical Care Survey & American Academy of Orthopaedic).
Hip fracture rates are increasing throughout urban Asia. A landmark study from Beijing 2002–2006 indicates the hip fracture incidence in those aged over 50 years to be 229/100,000 per year in women and 129/100,000 per year in men. This study found the rates of age-specific hip fractures in those aged over 50 years increased by 58% in women and by 49% in men. The same study also compared hip fractures that occurred from 2002-2006 with those that had occurred previously from 1990-1992, and it was found that the adjusted age-specific rates of hip fracture over age 50 years increased 2.76-fold in women and 1.61-fold in men. The increasing rate of hip fractures is serious since they are associated with increased mortality. In Mainland China, 1.8 million new osteoporotic vertebral fractures occurred in 2006. Since the number of people aged older than 60 years is expected to approach 438 million by 2050, it can be projected that the number of Chinese in this age group with osteoporotic vertebral fractures could reach 36.7 million and 48.5 million in 2020 and 2050, respectively. (Data Source: International Osteoporosis Foundation).
The demand for medical device equipment has rapidly increased during the last decade. Total market sales have increased more than 15% each year. The figures show that about 4 million bone bolts/screws are needed each year. Between 2005 and 2009, the total world-wide sales of clinical equipment and materials are over USD 2 trillion, and more than 50% of the sales are related to bio-materials.
China’s Market for PA Devices
China’s market for PA devices depends on 3 major conditions:
- patients
- advanced technology level
- performance and price of the materials.
In the first 50 years of the 21st century, China will have a growing aging population, while the total population in China will continually increase. New and improved medical technologies will be rapidly developed and utilized throughout hospitals in China, and material optimization and product pricing is expected to directly stimulate increased sales.
Competitive Analysis
Our Company is the only patent holder of PA technologies in China, as well as the only company carrying out Clinical Trials on PA products in China. At this time there are no similar products in this market (bio-degradable internal fixation devices that degrade without acids or other non-naturally occurring substances). Moreover, due to the nature of the regulatory environment, and the requirements and logistics of mounting a clinical trial, it would take any new competitor a minimum of three years to catch up to our lead in this area alone. Factoring in our established relationships with key customers, distributors, and regulators, as well as our ready-to-run production facilities, and our actual advantage is considerable longer than the 3 year regulatory advantage. This represents an invaluable window in which to firmly entrench our company as the preferred purveyor of self-reinforced, absorbable biodegradable PA components in the Chinese health care environment.
To reiterate, our company and product line offer several critical competitive advantages, specifically:
|
· |
There are no similar patent registrations in China. |
|
· |
Our initial product, the PA Screw, has completed 100% of the required clinical trials, with a 100% success rate, and now await the formality of CFDA approval. |
|
· |
We are the only company qualified and permitted to conduct clinical trials of other PA products by China’s CFDA. |
|
· |
We have a timing advantage over other companies in China, which would have to go through the preclinical testing before they could even apply for a permit to conduct actual clinical trials. |
|
· |
Under existing regulation structure, it will take at least 3 years for any competitor’s clinical trials to be completed, and total of 7 or more years to reach the point where we are now. |
Specific Competition
Competition in the medical implant device industry is intense both in China and in global markets. In orthopedics, ABMT’s principal competitors are the numerous companies that sell metal implants. ABMT competes with the manufacturers and marketers of metal implants by emphasizing the ease of implantation of the Company’s Self-Reinforced, Bio-absorbable, Brady-degradable implants, the cost effectiveness of such products, and the elimination of risks associated with the necessity of performing removal surgeries frequently required with less modern products.
Within the resorbable implant market, ABMT is competing with other manufacturers of resorbable internal fixation devices primarily on the basis of the physiological strength of ABMT’s polymers and the length of the strength retention time demonstrated by ABMT’s formulations. In order to replace the widely-used metal components, the new materials must meet numerous bioconsistency and mechanical-consistency requirements. Furthermore, they must also exhibit specific properties with respect to bio-activities, degradability, and controllable degradation speed. Although many macromolecule materials are degradable inside human body, relatively few provide the physical characters required for fracture fixation.
Our primary competition will be the generation-one and generation-two counterparts, which, despite their functional inferiority, enjoy the benefit of familiarity and an established manufacturing and marketing base. This competition comes from a number of entrenched players worldwide, including Acumed, Biomet, Inc., Conmed Corp., Encore Orthopedics, Exactech, Inc., Johnson & Johnson, DePuy, Inc., Medtronic Sofamor Danek, Inc., Orthofix International N.V., Smith and Nephew Plc, Stryker Corp., Synthes, Inion, Ltd. and others. Although many of these competitors have substantially greater resources upon which to draw, we are confident that the technological superiority of the more forward-looking product will ultimately equalize the playing field by orthopaedic innovation.
For the past 20 years, titanium has been the most widely used, and the most expensive material for fixing fractures (in both elective and emergency surgery). Although metal exhibits the desired strength and rigidity to allow the healing process to begin, there are a number of issues associated with using permanent titanium systems. Biodegradable plating systems deliver many of the benefits of their metal counterparts, without the disadvantages.
There are a number of marketers and manufacturers of PLA and PLLA--the first generation of Self-degradable, absorbable, orthopedic internal fixation devices in China. (Note: Titanium screws cost as much as $2200.)
| Competing products and prices in China (screw) |
| Producer |
Origin |
Brand |
Price (USD/PC)
|
| Arthrex |
Germany/USA
|
Arthrex |
$ 554.74 |
|
Conmed
|
USA |
Linvatec |
$ 554.74 |
|
Bionx
|
Finland |
Biofix |
$ 554.74 |
|
Gunze
|
Japan |
Grandfix |
$ 416.06 |
|
Takiron
|
Japan |
Fixsorb |
$ 408.76 |
|
Dikang
|
China |
PDLLA |
$ 321.17 |
|
ABMT
|
China |
ABMT |
$ 300.00 |
Other foreign companies that produce PLA, PLLA or titanium, stainless products, but have less marketing in China are:
· DePuy (Johnson & Johnson)
· Medtronic
· Stryker
· Zimmer
· Smith & Nephew
· Biomet
· Conmed
· Inion
Product advantage and Market Opportunity:
| - |
There are no similar patent registrations in China. |
| - |
We are the only company qualified and permitted to take clinical trials by China CFDA. |
| - |
We have a timing advantage over other companies in China which would have to go through the preclinical testing for the CFDA permit on Clinical Trials. |
| - |
Under existing regulation by CFDA, it will take at least 3-5 years to complete clinical trials for a new product similar to the Company’s PA Screw, which has finished all required clinical trials. |
Product Comparisons
Among many other advantages, a main advantage of ABMT’s proprietary PA technology is the elimination of the need for secondary surgery to remove an implantation device. Implant removal belongs to the most common elective orthopaedic procedures in industrial countries. In children, implant removal may be necessary to remove implants early to avoid disturbances to the growing skeleton, to prevent their bony immuring making later removal technically difficult or impossible, and to allow for planned reconstructive surgery after skeletal maturation (e.g., in case of hip dysplasia). In adults, pain, soft tissue irritation, the resumption of strenuous activities or contact sports after fracture healing, and the patient’s demand are typical indications for implant removal in clinical practice. However, implant removal requires a second surgical procedure in scarred tissue, and poses a risk for nerve damage and re-fractures. (cite: Hanson et al. BMC Musculoskeletal Disorders 2008)
| PHYSICAL COMPARISON |
| |
Metal |
PLLA |
ABMT’s PA devices |
| Strength |
Excellent |
Weak |
Superior to PLLA |
| Unit Cost |
High |
Low |
Lowest |
| Processability |
Good |
Good |
Good |
| Modulus of Elasticity |
Low: may cause infection,
may cause second
fracture
|
Moderate to Quite Fragile |
Excellent |
| Self-Reinforced |
No |
Yes, but degradation
starts too quickly
|
Yes |
| Self-Resorbable |
No1 |
Yes, but initial degradation
too fast in first few
weeks. Initial strength
down to 10~20Mpa in 4
weeks (close to osteoporosis)
|
Yes: unchanged during
first 12 weeks, hardness
remains 70% min
through week 20.
|
| Stretchability |
Strong |
50~60 Mpa |
170 Mpa (min) |
| Bone Healing |
Bone mineral density decrease averages 18% |
Bone mineral density decrease averages 7-10% |
Bone mineral density decrease less than 5% |
| Implant Failure Rate |
High to Medium |
Medium to Low |
Very Low |
| Need for Repeat Surgery |
As Required2 |
Only if failure (second fracture) |
No |
1 Titanium and aluminum has been traced in serum and hair of 16 of 46 patients after receiving titanium implants. (cite: Kasai Y, Iida R, Uchida A: Metal concentrations in the serum and hair of patients with titanium alloy spinal implants.)
2 Implant removal belongs to the most common elective orthopaedic procedures in the industrial countries. In a frequently cited Finnish study, implant removal contributed to almost 30% of all planned orthopaedic operations, and 15% of all operations. (cite: Bostman O, Pihlajamaki H: Routine implant removal after fracture surgery: a potentially reducible consumer of hospital resources in trauma units.)
Towards the end of the last century, spinal and orthopedic implants evolved towards progressively stronger and stiffer devices, as it was presumed that increased construct rigidity would optimize the biological milieu and provide more rapid and robust healing and arthrodesis. For the past 20 years, titanium has been the most widely used, and the most expensive material for fixing fractures (in both elective and emergency surgery). More than 1,000 tons (2.2 million pounds) of titanium devices of every description and function are implanted in patients worldwide each year. Although metal exhibits the desired strength and rigidity to allow the healing process to begin, there are a number of issues associated with using permanent titanium systems. Biodegradable systems deliver many of the benefits of their metal counterparts, without the disadvantages:
| |
METAL |
ABMT’s PA devices |
| Cranial Growth |
· Growth restriction
· Intracranial implant migration
|
· Stimulation of growth leading to better bone healing |
| Accumulation of Metal in tissues |
Yes |
No |
| Adverse Effect |
· Many necessitate removal operation either for mechanical strength of the overall structure
· majority of implant failures occur at the bone-screw interface with screw pullout being the most common mechanistic cause of construct failure
· should the bone fail to heal, these micromotions will persist and cause the metallic screw to oscillate within the far softer surrounding bone interface
|
None |
| Stiffness for optimal healing |
· Too stiff
· Stress shielding can result in bone atrophy and degradation
|
· Optimal stiffness/flexibility characteristics to achieve surgical fixation, while conforming to the softer, more pliable bone of the patient |
| Other Effects |
· Implant palpability
· Temperature sensitivity
· Occasionally visibility
· Could cause trauma in the event of mechanical failure
· Imaging and radiotherapy interference
· Potential for cross contamination
|
· No long-term palpability
· No temperature sensitivity
· Predictable degradation
· Reduced patient trauma
· No imaging and radiotherapy interference
· No second surgery required
|
| Cost of product |
Cost to hospital: $400-$2200 |
Cost to hospital: $300 |
Intellectual Property
The Company has been granted one patent for its material by the State Intellectual Property Office of the P.R.C. Patent no. ZL971190739, PRC. This patent also protects the use and manufacturing process of the material.
Chinese Patent
| Title: High molecular human body embedding article and its preparing process product and use |
| Application Number: |
97119073 |
Application Date: |
1997.10.22 |
| Publication Number: |
1214939 |
Publication Date: |
1999.04.28 |
| Approval Pub. Date: |
|
Granted Pub. Date: |
2002.08.14 |
| International Classification: |
A61F2/02,A61L27/00,C08L33/00 |
| Applicant(s) Name: |
Liu Jianyu |
| Address: |
518111 |
| Inventor(s) Name: |
|
| Attorney & Agent: |
Li Zhi Ning |
Abstract
The present invention discloses a macromolecular implant for human body and its preparation process, and relates to the products made up by using said macromolecular implant and their application. Said invented product is made up by using resin fibre through hot-pressing treatment according to the formula provided by said invention, and its strength is high, tenacity is good and its shape can be processed according to the requirement in the period of bone union after implantation, and said implant can be made into the fixation block, eurymeric block, fastening piece and suture for reduction of fracture, and can be started to be degraded from twenty-fourth week after implantation, and can be completely absorbed by human body after 1.5-2 years, and its cost is low.
Employees
As of October 31, 2015, we had 24 employees, with 11 employees in R&D, Clinical and Regulatory, 5 employees in Manufacturing, 3 employees in Sales & Marketing, 4 employees in General and Administration, and 1 employee in Accounting. The Company intends to offer more engineer positions in future.
We believe that our future success will depend in part on our continued ability to attract, hire and retain qualified personnel. None of our employees are represented by a labor union, and our employee relations have been good.
The company’s facilities are located at Block A, Longcheng Tefa Industrial park, Longgang, Shenzhen, China.
Availability of new qualified employees
Shenzhen is located in the southern part of the Guangdong Province, on the eastern shore of the Pearl River Delta. Neighboring the Pearl River Delta and Hong Kong, Shenzhen’s location gives it a geographical advantage for economic development.
Shenzhen’s well-built market economy and diversified culture of migration have helped to create the best-developed and most dynamic market economy in China. Shenzhen is China’s first special economic zone. After more than 30 years of development, Shenzhen has grown into a powerful city boasting the highest per capita GDP in China’s mainland. Its comprehensive economic capacity ranks among the top of the country’s big cities. The combined value of imports and exports has remained No.1 for 20 years in China’s foreign trade.
Since 1997, China has accelerated the development of higher education and increased enrollment in regular universities and colleges. Between 2003 and 2015 the number of students completing undergraduate and graduate courses in China more than tripled, from 2.12 million to 7.49 million graduates.
Guangdong has entered a transition period from an elite education to a popularized higher education. There are 120 universities and colleges offering higher education in Guangdong province with over 519,000 students graduated in 2015. Combined with graduates from other parts of China, there are over 800,000 job-seeking graduates in total in Guangdong in 2015. 94.80% of the graduates from Guangdong have successfully found their first employment, and more than 80% of these employments are based in Pearl River Delta.
Insurance
While we are carrying out the Clinical Trials, we do not have any Product Liability Insurance coverage for the use of our proposed products. We intend to obtain Product Liability Insurance coverage for commercial sale of our products in due course.
Government Regulations
Our primary target market is the medical community of the People’s Republic of China (PRC). Medical devices manufactured by the Company in China are subject to regulation by the China Food and Drug Administration (“CFDA”), formally the State Food and Drug Administration (“SFDA”) of the PRC. The manufacturing facilities are also required to meet China’s Good Manufacturing Practices (“GMP”) standards.
The Company’s production facilities are fully compliant with GMP requirements. The Company’s CFDA Application for its PA Screw is under the CFDA Review Process.
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
| ITEM 1B. |
UNRESOLVED STAFF COMMENTS |
There are no unresolved comments from the SEC.
None.
| ITEM 3. |
LEGAL PROCEEDINGS |
We are not involved in any pending or imminent litigations or current legal proceedings.
ITEM 4. MINE SAFETY DISCLOSURE
Not applicable.
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Only a limited market exists for our securities. There is no assurance that a regular trading market will develop, or if developed, that it will be sustained. Therefore, a shareholder in all likelihood will be unable to resell his securities in our company. Furthermore, it is unlikely that a lending institution will accept our securities as pledged collateral for loans unless a regular trading market develops.
Our company’s securities are traded on the world’s largest electronic interdealer quotation system “OTCQB” operated by the OTC Markets Group under the symbol “ABMT”.
| Fiscal Quarter |
|
High Bid |
|
|
Low Bid |
|
| 2015 |
|
|
|
|
|
|
|
|
| Fourth Quarter 08-01-15 to 10-31-15 |
|
$ |
0.20 |
|
|
$ |
0.14 |
|
| Third Quarter 05-01-15 to 07-31-15 |
|
$ |
0.15 |
|
|
$ |
0.14 |
|
| Second Quarter 02-01-15 to 04-30-15 |
|
$ |
0.20 |
|
|
$ |
0.14 |
|
| First Quarter 11-01-14 to 01-31-15 |
|
$ |
0.43 |
|
|
$ |
0.20 |
|
| Fiscal Quarter |
|
High Bid |
|
|
Low Bid |
|
| 2014 |
|
|
|
|
|
|
| Fourth Quarter 08-01-14 to 10-31-14 |
|
$ |
0.51 |
|
|
$ |
0.43 |
|
| Third Quarter 05-01-14 to 07-31-14 |
|
$ |
1.00 |
|
|
$ |
0.51 |
|
| Second Quarter 02-01-14 to 04-30-14 |
|
$ |
0.65 |
|
|
$ |
0.60 |
|
| First Quarter 11-01-13 to 01-31-14 |
|
$ |
0.95 |
|
|
$ |
0.65 |
|
Shareholders
At October 31, 2015, we had 40 shareholders of record of our common stock, including shares held by brokerage clearing houses, depositories or otherwise in unregistered form. We have no outstanding options or warrants, or other securities convertible into, common equity.
Dividend Policy
We have not declared any cash dividends. We do not intend to pay dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.
Section 15(g) of the Securities Exchange Act of 1934
Our shares are covered by section 15(g) of the Securities Exchange Act of 1934, as amended that imposes additional sales practice requirements on broker/dealers who sell such securities to persons other than established customers and accredited investors (generally institutions with assets in excess of $5,000,000 or individuals with net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouses). For transactions covered by the Rule, the broker/dealer must make a special suitability determination for the purchase and have received the purchaser’s written agreement to the transaction prior to the sale. Consequently, the Rule may affect the ability of broker/dealers to sell our securities and also may affect your ability to sell your shares in the secondary market.
Section 15(g) also imposes additional sales practice requirements on broker/dealers who sell penny securities. These rules require a one-page summary of certain essential items. The items include the risk of investing in penny stocks in both public offerings and secondary marketing; terms important to in understanding of the function of the penny stock market, such as “bid” and “offer” quotes, a dealers “spread” and broker/dealer compensation; the broker/dealer compensation, the broker/dealers duties to its customers, including the disclosures required by any other penny stock disclosure rules; the customers rights and remedies in causes of fraud in penny stock transactions; and, the FINRA’s toll free telephone number and the central number of the North American Administrators Association, for information on the disciplinary history of broker/dealers and their associated persons.
Securities authorized for issuance under equity compensation plans
We have no equity compensation plans and accordingly we have no shares authorized for issuance under an equity compensation plan.
| ITEM 6. |
SELECTED FINANCIAL DATA |
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.
| ITEM 7. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this annual report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.
Overview
The following discussion is an overview of the important factors that management focuses on in evaluating our businesses, financial condition and operating performance and should be read in conjunction with the financial statements included in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward looking statements as a result of any number of factors, including those set forth in this Annual Report on Form 10-K, and elsewhere in our other public filings. Factors that may cause actual results, our performance or achievements, or industry results to differ materially from those contemplated by such forward-looking statements include without limitation:
|
1. |
The company’s lack of funds in new R&D, especially in clinical testing; |
|
2. |
The company’s lack of funds in new equipment and the utilization of the production process after CFDA approval; |
|
3. |
The company may need to seek funding through such vehicles as convertible notes and warrants, private placements, and/or convertible debentures; |
|
4. |
The company needs funding for marketing and network build-up; |
|
5. |
The company plans to seek approval for clinical testing and marketing on a worldwide basis, including US FDA approval for testing and marketing in the United States of America, and there is no guaranty that we will obtain any such approval; |
|
6. |
While the company currently holds a patent originating in China, the patent does not protect our intellectual property in the United States, and the company is unsure of the validity of the patent in other countries. However, specific trade secrets are involved in the manufacturing of our product to help protect our technologies, and reverse engineering is unlikely for our types of products and technologies. Additionally, all machinery used to manufacture our products is protected by Chinese patents. |
The Company is subject to a number of risks similar to other companies in the medical device industry. These risks include rapid technological change, uncertainty of market acceptance of our products, uncertainty of regulatory approval, competition from substitute products from larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, product liability, and the dependence on key individuals.
All written and oral forward-looking statements made in connection with this Form 10-K that are attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given the uncertainties that surround such statements, you are cautioned not to place undue reliance on such forward-looking statements.
Our Business
We are engaged in the business of designing, developing, manufacturing and the planned future marketing of self-reinforced, re-absorbable biodegradable internal fixation devices. Our polyamide materials are protected by Patent no. ZL971190739, PRC, issued by the State Intellectual Property Office of the P.R.C., is used in producing screws, binding wires, rods and related products. These products are used in a variety of applications, which include orthopedic trauma, sports related medical treatment, or cartilage injuries, and reconstructive dental procedures. Our products are biodegradable internal fixation devices which are made of a very unique material called Polyamide (“PA”). Our PA products, such as screws, rods, and binding wires consist of enhanced fibers and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system. Our products offer a number of significant advantages over existing metal implants and the first generation of degradable implants (i.e. PLLA) for patients, surgeons and other customers including:
|
1. |
A notably reduced need for a secondary surgery to remove implant due to post-operative complications, therefore avoiding unnecessary risk and expense on all patient care; |
|
2. |
Enhancing the performance of the materials by manufacturing them to be easily fitted to each patient, forming an exact fit; |
|
3. |
Improving the biological activity of materials. Clinical trial results have shown that as PA implants degrade, they promote a progressive shift of load to the new bone creating micro-motion and thereby avoiding bone atrophy due to ’stress shielding’; |
|
4. |
Reducing the chance of post-operative infection; |
|
5. |
Effectively controlling the degeneration speed, so that there will be no complications in treating repeat injuries; |
|
6. |
Ease of post-operative care i.e. no distortion during x-ray imaging; |
|
7. |
Simple and cost-effective to manufacture. |
Our products are designed to replace the traditional internal fixation device made of stainless steel and titanium and overcome the limitations of previous generations of products such as PLA and PLLA. Our laboratory statistics show that our PA products have a higher mechanical strength, last longer in degradation ratio and are more evenly absorbed form outer layer inwards as compared with similar materials such as PLA and PLLA. Thus PA allows increased restoration time for bone healing and re-growth. The Company’s PA Degradable and Absorbable Screw (“PA Screw”) and Degradable and Absorbable Binding Wire (“PA Binding Wire) are currently being tested in human trials under permit from the China Food and Drug Administration (“CFDA”). As of October 31, 2015, the Company completed 83 successful PA Screw trial cases, and 57 successful PA Binding Wire. Upon the completion of these trials the Company has already exceeded China CFDA’s requirement on PA Screw trial. The Company’s CFDA Application for its PA Screw is in the CFDA Review Process.
CFDA Application Process for PA Screws
The Company first submitted its application for PA Screws to the CFDA, formally SFDA, in 2008. The application has been withheld by the CFDA pending additional clinical trial cases. This is due to the amended CFDA regulations, which unlike previous regulations require the applicant to specify the position on the body where the clinical trial is carried out. Our amended CFDA application has specified the ankle fracture as the body part of our clinical trial. This is because bones around this part carry most of the body weight. As of October 31, 2011, we have completed all additional clinical trials required by the CFDA with 100 percent success rate. As of October 31, 2015, the company’s CFDA Application is under the CFDA Review Process.
In March 2013, The State Food and Drug Administration of the PRC (“SFDA”), China’s medical device market regulatory agency, underwent a reorganization that saw much of China’s food and drug regulatory powers consolidated into the agency, elevating it back to a ministerial-level agency directly under the State Council. The new name for the agency is China State Food and Drug Administration (“CFDA”). The name change meant the CFDA reports directly to China’s State Council and has broader authority to oversee medical device as well as food and drug sectors. This reorganization leads to a more streamlined and efficient registration process for medical devices in China. Since the reorganization, the CFDA has issued series of circulars and guidelines to help applicants. Following the CFDA guidelines, the Company has improved its GMP facilities, updated its Technical Documentation System to cover key areas such as Clinical Trial, Manufacturing Process, R&D, Monitoring and Quality Control. Due to the uniqueness of our material, there are no established CFDA Product Standards that we can follow during our application process for our PA Screws. To establish our own Product Standards, the Company has been carrying out extra tests. The Company has submitted its Product Standards and supplementary reports to the CFDA in 2014. We expected the CFDA approval for our PA Screws to be granted in 2016.
The Company’s production lines are fully operational. We have been producing products for further researches, testing and product quality control improvements. Following the CFDA final approval, the company will be earning revenues in the same quarter that its application is approved. However, we are not able to anticipate the timeline of the CFDA Review Process.
Clinical Trials on Other Products
Currently, we have been conducting clinical trials for PA Binding Wires at the 6 state level hospitals authorized by the CFDA in cities throughout China, including Nanchang, Changsha, Luoyang, Nanning and Tianjin. We have successfully completed all 60 clinical human trial cases required by the CFDA, and we have completed 42 comparison cases. CFDA regulations require each successful clinical trial case to be accompanied by a trial case that uses a different product for comparison reasons. We intended to start CFDA Application Process for our PA Binding Wires when we complete the remaining 18 comparison cases.
The Company has setup a joint research project with Sichuan University. The Company has completed the design and production of testing mini-screws using its patented PA material. This project is currently under way.
However, there can be no assurance that the company will be able to obtain any further clearances or approvals, if required, to market its products for their intended uses on a timely basis, if at all. Moreover, regulatory approvals, if granted, may include significant limitations on the indicated uses for which a product may be marketed. Delays in the receipt of or the failure to obtain such clearances or approvals, the need for additional clearances or approvals, the loss of previously received clearances or approvals, unfavorable limitations or conditions of approval, or the failure to comply with existing or future regulatory requirements could have a material adverse effect on the Company’s business, financial condition and results of operations.
Government Regulation
Medical implant devices/products manufactured or marketed by the company in China are subject to extensive regulations by the CFDA. Pursuant to the related laws and acts, as amended, and the regulations promulgated there under (the “CFDA Regulations”), the CFDA regulates the clinical testing, manufacture, labeling, distribution and promotion of medical devices. The CFDA also has the authority to request repair, replacement, or refund of the cost of any device manufactured or distributed by the Company.
Under the CFDA Regulations, medical devices are classified into three classes (class I, II or III), the basis of the controls deemed necessary by the CFDA to reasonably assure their safety and efficacy. Under the CFDA’s regulations, class I devices are subject to general controls [for example, labeling and adherence to Good Manufacturing Practices (“GMP”) requirements] and class II devices are subject to general and special controls. Generally, class III devices are those, which must receive premarket approval by the CFDA to ensure their safety and efficacy (for example, life-sustaining, life-supporting and certain implantable devices, or new devices which have not been found substantially equivalent to legally marketed class I or class II devices). The Company is classified as a manufacturer of class III medical devices. Current CFDA enforcement policy prohibits the marketing of approved medical devices for unapproved uses.
Before a new device can be introduced into the market in China, the manufacturer generally must obtain CFDA marketing clearance through clinical trials. Since the company is classified as a manufacturer of Class III medical devices, the company must carry out all clinical trials in pre-selected CFDA approved hospitals.
Manufacturers of medical devices for marketing in China are required to adhere to GMP requirements. Enforcement of GMP requirements has increased significantly in the last several years and the CFDA has publicly stated that compliance will be more strictly scrutinized. From time to time the CFDA has made changes to the GMP and other requirements that increase the cost of compliance. Changes in existing laws or requirements or adoption of new laws or requirements could have a material adverse effect on the company’s business, financial condition and results of operations. There can be no assurance that the company will not incur significant costs to comply with applicable laws and requirements in the future or that applicable laws and requirements will not have a material adverse effect upon the company’s business, financial condition and results of operations.
Regulations regarding the development, manufacturing and sale of the company’s products are subject to change. The company cannot predict the impact, if any, that such changes might have on its business, financial condition and results of operations.
Results of Operations
The “Results of Operations” discussed in this section merely reflect the information and results of Masterise and Shenzhen Changhua for the years ended October 31, 2015 and 2014.
Revenues
The Company is in its development stage and does not have any revenue. The management team is continuously looking for fundraising possibilities for product improvement, machinery upgrades, facility expansions, continuous research and development, and sales and marketing preparation.
Our facility is located in Shenzhen, China, which is built to meet the GMP standards. Our facility covers about 865 square meters, which includes the combined facilities of offices, laboratories, and workshops. There is one production line for the PA Screw and another production line for the PA Binding Wire. The annual production capabilities of each production line are 100,000 pieces for PA Screw, and 240,000 packs for the PA Binding Wires. Both production lines, at their maximum production capacities are capable of generating approximately $30,000,000 in annual revenue.
| Estimate current production lines in full capacity |
|
|
Output Quantity (Max.) |
|
Price at
ex-factory
(US$) |
|
|
Total
Turnover
(US$) |
|
| PA Screw |
100,000 |
(piece) |
|
|
180 |
|
|
|
18,000,000 |
|
| PA Binding Wire |
240,000 |
(pack) |
|
|
50 |
|
|
|
12,000,000 |
|
|
|
|
Total: |
|
|
|
30,000,000 |
|
The Company will market its products through a hybrid sales force comprised of a managed network of independent regional distributors/sales agents (80%) and direct sales representatives (20%) in China.
There are two ways the company will generate revenue, 1) through our nationwide and regional distributors and 2) through our direct sales channels.
Funding Needs
The Company estimates that it will need to raise minimum $750,000 over the next 12 months to bring its current products to market, and begin earning revenues. This amount may increase if we decide to start clinical trials on new products. Once we receive the CFDA permit for our PA Screw, our revenue will cover our expenditures. Otherwise, we will continue to rely on external investments and shareholder’s loans to meet our cash needs. While the Company has no outside sources of funding, the Company’s shareholders have committed to advance the Company funds as needed. There is a Letter of Continuing Financial Support signed between the Company and two of its major shareholders and related party, Titan Technology Development Ltd, Ms. Hui Wang and Mr. Chi Fung Yu.
China’s Marketing Analysis and Sales Strategy
We have established long term relationships with many hospitals and national distributors in China. Ms. Hui Wang, the Company’s CEO, has over 20 years sales experience in medical distribution. She will be in charge of our sales programs. Professor LIU, Shangli, our chief medical advisor for Greater China, is one of the highest ranked orthopedic doctors in China as well as being highly renowned in the rest of the world. He will assist the Company in nationwide product promotion and joint projects with associated academic institutions and medical schools.
During product development and clinical trial stages we developed close relationships with many major national hospitals. We expect these relationships to boost our revenue generation following CFDA final approval. In order to better serve our customers, including hospitals, distributors, patients and the general public, the Company will set up Regional Service Offices to provide technical support, product information, and customer aid service.
China’s market for PA devices depends on 3 major conditions:
- Patients
- Advanced technology level
- Performance and price of the materials
The demand for internal fixation medical devices has rapidly increased during the last decade. According to China Health Care Year Book 2013, the total revenue of Chinese orthopaedic hospitals in 2013 was US$1.28 billion with over 11.5 million patients. From 2009 to 2013, the market size of China’s orthopaedic devices has grown from US$1.1 billion to US$1.92 billion, and it is estimated to reach US$2.55 billion in 2015, to overtake Japan as the second largest market in the world. The market size for trauma treatment implant devices such as our PA Screw and PA Wire was US$626.3 million or 32.6% of the total market value in 2013, and it is estimated to grow to US$1.164 billion in 2019. New and improved medical technology will continue to rapidly grow throughout hospitals in China, and material optimization and product pricing is expected to directly stimulate increased sales.
The Company has advantages and more opportunities over others competitors due to:
- No other similar patent registrations in China.
- We are the only company qualified and permitted to perform PA clinical trials by the CFDA
- We have a timing advantage over other companies in China, which would have to go through the preclinical testing for the CFDA permit on clinical trials.
- Under new regulations by the CFDA, it will take at least 5-10 years for clinical trials.
- Our patented material will enables us to rapidly diversify our product line according to market trend and demand.
Number of Hospitals in China in year 2015 Statistic and Census report by the National Health and Family Planning Commission of the People’s Republic of China.
| Statistic and Census report by National Health and Family Planning Commission of the People’s Republic of China |
| |
| (September 2015) |
| |
|
|
|
| |
September 2015 |
September 2014 |
Increase /
(Decrease) |
| Total No. of Hospitals |
26,904 |
25,304 |
1,600 |
| Public Hospital |
13,304 |
13,341 |
(37) |
| Private Hospital |
13,600 |
11,963 |
1,637 |
| Hospital Rating |
|
|
|
| AAA |
2,032 |
1,875 |
157 |
| AA |
7,080 |
6,764 |
316 |
| A |
7,464 |
6,774 |
690 |
In general, technological advancements and the marketing potential within Asia are the biggest factors in driving significant growth within the global orthopedic devices market. Another major factor that positively influences this market is the growing number of aging baby boomers with active lifestyles. This sector represents a large portion of the total population.
Research and Development
Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2015 and 2014 was $60,202 and $47,700.
We expect research and development expenses to grow as we continue to invest in basic research, clinical trials, product development and in our intellectual property.
Pre-Market Research
The Company has been conducting Pre-Market Research while its PA Screw Application is under CFDA review. The research is intended to estimate the potential market success of the company’s products that can be expected. The research also looks beyond the Company’s initial market - China, and covers international markets. Based on the results of our Pre-Market Research and the positive feedbacks, we have received from trade shows and industrial conferences, it is the Company’s intention to apply for additional international regulatory approvals in due course.
Finance Costs
As of October 31, 2015 and 2014, the Company owed $562,187 and $459,131 respectively to a stockholder – Titan Technology Development Limited, which is unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed.
As of October 31, 2015 and 2014, the Company owed $27,229 and $0 respectively to Shenzhen Hygeian Medical Device Co., Ltd., which is unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed.
As of October 31, 2015 and 2014, the Company owed $1,807,103 and $1,618,333 to Chi Fung Yu, $1,660,763 and $1,370,405 to Tie Jun Chen, $33,133 and $0 to Que Feng (related parties), which are unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed.
Total interest expenses on advances from a stockholder accrued for the year ended October 31, 2015 and October 31, 2014 are $31,615 and $26,081 for Titan Technology Development Limited.
Total interest expenses on advances from following company accrued for the year ended October 31, 2015 and October 31, 2014 are $144 and $0 for Shenzhen Hygeian Medical Device Co., Ltd.
Total interest expenses on advances from following related parties accrued for the year ended October 31, 2015 and October 31, 2014 are $99,978 and $87,351 for Chi Fung Yu; $87,089 and $67,961 for Tie Jun Chen; $1,495 and $0 for Que Feng.
As of October 31, 2015 and October 31, 2014, the Company owed the following amounts respectively to two directors for advances made - $417,966 and $382,280 to Hui Wang, $21,897 and $20,230 to Chi Ming Yu. These advances were made on an unsecured basis, repayable on demand and interest free.
Imputed interest on the amounts owed to two directors for the year ended October 31, 2015 and 2014 respectively is $21,164 and $20,079 for Hui Wang; $0 and $0 for Chi Ming Yu.
Income Tax
ABMT was incorporated in the United States and has incurred net operating loss for income tax purposes for 2015 and 2014. ABMT has net operating loss carry forwards for income taxes amounting to approximately $1,612,970 and $1,512,723 as of October 31, 2015 and 2014 respectively which may be available to reduce future years’ taxable income. These carry forwards, will expire, if not utilized, commencing in 2029. Management believes that the realization of the benefits from these losses appears uncertain due to the Company’s limited operating history and continuing losses. Accordingly, a full, deferred tax asset valuation allowance has been provided and no deferred tax asset valuation allowance has been provided and no deferred tax asset benefit has been recorded. The valuation allowance at October 31, 2015 and 2014 was $548,410 and $514,326 respectively. The net change in the valuation allowance for 2014 was an increase of $34,084.
Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.
Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been 25%. No income tax expense has been provided by Shenzhen Changhua as it is waiting for CFDA approval and it has incurred losses.
Net Loss
As reflected in the accompanying audited consolidated financial statements, the Company has an accumulated deficit of $6,262,961 at October 31, 2015 that includes a net loss of $862,854 for the year ended October 31, 2015. We are in Clinical Trial phase and do not have a CFDA permit to produce, market or sell in China.
We therefore do not have any revenue from inception to October 31, 2015 but have to incur operating expenses for the upkeep of the Company and the clinical trials.
Liquidity and Capital Resources
We had a working capital deficit of $4,568,106 at October 31, 2015 compared to a working capital deficit of $3,863,028 as of October 31, 2014. Our working capital deficit increased as a result of the fact that we are in clinical trial phase, the company has put all resources to complete the clinical trials. We do not have a CFDA permit to produce, market or sell in China. We had no revenues during the year and that our sole source of financing came in the form of a loan from our related parties and stockholders.
Cash Flows
Net Cash Used in Operating Activities
Net cash used in operating activities was $820,393 in the year ended October 31, 2015. This amount was attributable primarily to the net loss after adjustment for non-cash items, such as depreciation and imputed interest on advances from directors.
Net Cash Used in Investing Activities
We recorded $16,412 net cash used in investing activities in the year ended October 31, 2015. This amount reflected purchases of property and equipment, primarily for research and development to our facilities.
Net Cash Provided by Financing Activities
Net cash provided by financing activities in the year ended October 31, 2015 was $801,975, which represented advances from related parties.
Operating Capital and Capital Expenditure Requirements
Our ability to continue as a going concern and support the commercialization of current products is dependent upon our ability to obtain additional financing in the near term. We anticipate that such funding will be in the form of equity financing from sales of our common stock. However, there is no assurance that we will be able to raise sufficient funding from the sale of our common stock to fund our business plan should we decide to proceed. We anticipate continuing to rely on advances from our related parties and stockholders in order to continue to fund our business operations.
We believe that our existing cash, cash equivalents at October 31, 2015, will be insufficient to meet our cash needs. The management is actively pursuing additional funding and strategic partners, which will enable the Company to implement our business plan, business strategy, to continue research and development, clinical trials or further development that may arise.
Debt Conversion
On November 13, 2015, the Company entered into a debt conversion agreement with Titan Technology Development Ltd., pursuant to which the Company and Titan agreed to convert $500,000 of the accrued interest of the outstanding debt owed by the Company to Titan into shares of the Company’s Common Stock at a conversion price of $0.05 per share. Pursuant to the terms of the Debt Conversion Agreement, on November 13, 2015, $500,000 of the accrued interest of TTD’s outstanding loan was converted into 10,000,000 shares of Company Common Stock.
Going Concern
As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $6,262,961 as of October 31, 2015 that includes a net loss of $862,854 for the year ended October 31, 2015. The Company’s total current liabilities exceed its total current assets by $4,568,106 and the Company used cash in operations of $820,393.
These factors raise substantial doubt about our ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent up the Company’s ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Management has taken steps to revise its operating and financial requirements, which it believes are sufficient to provide the Company with the ability to continue as a going concern. The Company is now pursuing additional funding and potential merger or acquisition candidates, which would enhance stockholders’ investment. Management believes that the above actions will allow the Company to continue operations through the next fiscal year.
As of October 31, 2015, loans from the Company’s stockholder, two directors, three related parties and a non-related third party totaling $3,968,091 were provided to us for use as working capital. Management believes that such financing will allow us to continue operations through the next fiscal year. The Company is also actively pursuing a number of private placements funding which would ensure continued operations.
OFF-BALANCE SHEET ARRANGEMENTS
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our investors.
CRITICAL ACCOUNTING POLICIES
The preparation of our financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including but not limited to those related to income taxes and impairment of long-lived assets. We base our estimates on historical experience and on various other assumptions and factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Based on our ongoing review, we plan to adjust to our judgments and estimates where facts and circumstances dictate. Actual results could differ from our estimates.
We believe the following critical accounting policies are important to the portrayal of our financial condition and results and require our management’s most difficult, subjective or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain.
|
1. |
Property and equipment |
Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.
Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.
In accordance with FASB Codification Topic 360 (ASC Topic 360), “Accounting for the impairment or disposal of Long-Lived Assets”, long-lived assets and certain identifiable intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, the recoverability test is performed using undiscounted net cash flows related to the long-lived assets. The Company reviews long-lived assets to determine that carrying values are not impaired.
Long-lived assets, such as property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income. For the year ended October 31, 2015 and 2014, the company has not recognized any impairment charges.
|
3. |
Fair value of financial instruments |
FASB Codification Topic 825 (ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses, other payables and accrued expenses, due to a stockholder, directors and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.
Government grants are recognized when there is reasonable assurance that the Company complies with any conditions attached to them and the grants will be received.
The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.
|
6. |
Research and Development |
Research and development costs related to both present and future products are expensed as incurred.
|
7. |
Foreign currency translation |
The financial statements of the Company’s subsidiary denominated in currencies other than US $ are translated into US $ using the closing rate method. The balance sheet items are translated into US $ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.
Recent Accounting Pronouncements
In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Accounting Standards Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met conditions which would subject these financial statements for additional disclosure.
| ITEM 7A. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.
| ITEM 8. |
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
ADVANCED BIOMEDICAL TECHNOLOGIES, INC.
AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
AS OF OCTOBER 31, 2015
ADVANCED BIOMEDICAL TECHNOLOGIES, INC.
AND SUBSIDIARIES
CONTENTS
|
AWC (CPA) LIMITED
Certified Public Accountants (Practising)
 |
|
7th Floor, Nan Dao Commercial Building, 359-361 Queen’s Road Central, Hong Kong.
Tel : (852) 2851 7954 Fax: (852) 2545 4086
|
To the Board of Directors and Shareholders of Advanced Biomedical Technologies, Inc. and subsidiaries
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have audited the accompanying consolidated balance sheets of Advanced Biomedical Technologies, Inc. and subsidiaries (“the Company”) as of October 31, 2015 and the related consolidated statements of operations, stockholders’ equity and cash flows for the year ended October 31, 2015. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.
We conducted our audit in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
We were not engaged to examine management’s assertion about the effectiveness of the Company’s internal control over financial reporting as of October 31, 2015 included in the Company’s Item 9A “Controls and Procedures” in the Annual Report on Form 10-K and, accordingly, we do not express an opinion thereon.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company as of October 31, 2015 and the results of its operations and its cash flows for the year ended October 31, 2015 in conformity with accounting principles generally accepted in the United States of America.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 10 to the financial statements, the Company had a net loss of $862,854, an accumulated deficit of $6,262,961 and a working capital deficiency of $4,568,160 and used cash in operations of $820,393. These factors raise substantial doubt about its ability to continue as a going concern. Management’s plans concerning this matter are also described in Note 10. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/ AWC (CPA) Limited
Certified Public Accountants
Hong Kong, China
February 16, 2016
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors of:
Advanced Biomedical Technologies, Inc.
We have audited the accompanying consolidated balance sheets of Advanced Biomedical Technologies, Inc. and subsidiaries, as of October 31, 2014 and 2013, and the related consolidated statements of operations and comprehensive loss, stockholders’ deficit and cash flows for the years ended October 31, 2014 and 2013. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits of the financial statements provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Advanced Biomedical Technologies, Inc. and subsidiaries, as of October 31, 2014 and 2013, the results of its operations and its cash flows for the years ended October 31, 2014 and 2013 in conformity with accounting principles generally accepted in the United States of America.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 9 to the financial statements, the Company had a net loss of $827,756, an accumulated deficit of $5,400,107 and a working capital deficiency of $3,863,028 and used cash in operations of $732,421. These factors raise substantial doubt about its ability to continue as a going concern. Management’s plans concerning this matter are also described in Note 9. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/ Baker Tilly Hong Kong Limited
BAKER TILLY HONG KONG LIMITED
Certified Public Accountants
Hong Kong
January 29, 2015
ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
| |
|
|
|
|
|
|
|
|
| |
|
October 31, |
|
|
October 31, |
|
| |
|
2015 |
|
|
2014 |
|
| |
|
|
|
|
|
|
|
|
| ASSETS |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| CURRENT ASSETS |
|
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
$ |
38,304 |
|
|
$ |
74,354 |
|
| Inventories |
|
|
2,791 |
|
|
|
— |
|
| Other receivables and prepaid expenses |
|
|
18,118 |
|
|
|
18,768 |
|
| Due from related parties |
|
|
— |
|
|
|
— |
|
| Total Current Assets |
|
|
59,213 |
|
|
|
93,122 |
|
| |
|
|
|
|
|
|
|
|
| Property and equipment, cost |
|
|
504,721 |
|
|
|
488,298 |
|
| Less: Accumulated depreciation |
|
|
(398,102 |
) |
|
|
(380,044 |
) |
| PROPERTY AND EQUIPMENT, NET |
|
|
106,619 |
|
|
|
108,254 |
|
| |
|
|
|
|
|
|
|
|
| DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT |
|
|
— |
|
|
|
16,238 |
|
| TOTAL ASSETS |
|
$ |
165,832 |
|
|
$ |
217,614 |
|
| |
|
|
|
|
|
|
|
|
| LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
| Other payables and accrued expenses |
|
$ |
97,041 |
|
|
$ |
105,771 |
|
| Due to directors |
|
|
439,863 |
|
|
|
402,510 |
|
| Due to a stockholder |
|
|
562,187 |
|
|
|
459,131 |
|
| Due to related parties |
|
|
3,528,228 |
|
|
|
2,988,738 |
|
| Total Current Liabilities |
|
|
4,627,319 |
|
|
|
3,956,150 |
|
| |
|
|
|
|
|
|
|
|
| COMMITMENTS AND CONTINGENCIES |
|
|
— |
|
|
|
— |
|
| |
|
|
|
|
|
|
|
|
| STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| Common stock, $0.00001 par value, 100,000,000 shares authorized, 56,874,850 shares issued and outstanding as of October 31, 2015 and October 31, 2014 |
|
|
569 |
|
|
|
569 |
|
| Additional paid-in capital |
|
|
1,949,132 |
|
|
|
1,927,968 |
|
| Deferred stock compensation |
|
|
— |
|
|
|
— |
|
| Accumulated deficit |
|
|
(6,262,961 |
) |
|
|
(5,400,107 |
) |
| Accumulated other comprehensive loss |
|
|
(148,227 |
) |
|
|
(266,966 |
) |
| Total Deficit |
|
|
(4,461,487 |
) |
|
|
(3,738,536 |
) |
| |
|
|
|
|
|
|
|
|
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
$ |
165,832 |
|
|
$ |
217,614 |
|
The accompanying notes are an integral part of these consolidated financial statements
ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| |
|
|
|
|
|
|
| |
|
Year ended |
|
| |
|
October 31, |
|
|
October 31, |
|
| |
|
2015 |
|
|
2014 |
|
| OPERATING EXPENSES |
|
|
|
|
|
|
|
|
| General and administrative expenses |
|
$ |
514,540 |
|
|
$ |
543,414 |
|
| Depreciation |
|
|
30,451 |
|
|
|
26,640 |
|
| Research and development |
|
|
60,202 |
|
|
|
47,700 |
|
| Total Operating Expenses |
|
|
605,193 |
|
|
|
617,754 |
|
| |
|
|
|
|
|
|
|
|
| LOSS FROM OPERATIONS |
|
|
(605,193 |
) |
|
|
(617,754 |
) |
| |
|
|
|
|
|
|
|
|
| OTHER (EXPENSES) INCOME |
|
|
|
|
|
|
|
|
| Government grants |
|
|
— |
|
|
|
— |
|
| Interest income |
|
|
119 |
|
|
|
137 |
|
| Interest paid to a stockholder and related parties |
|
|
(220,291 |
) |
|
|
(181,393 |
) |
| Imputed interest |
|
|
(21,164 |
) |
|
|
(20,079 |
) |
| Other, net |
|
|
(16,325 |
) |
|
|
(8,667 |
) |
| Total Other (Expenses) Income, net |
|
|
(257,661 |
) |
|
|
(210,002 |
) |
| |
|
|
|
|
|
|
|
|
| LOSS BEFORE TAXES |
|
|
(862,854 |
) |
|
|
(827,756 |
) |
| Income tax expense |
|
|
— |
|
|
|
— |
|
| NET LOSS |
|
|
(862,854 |
) |
|
|
(827,756 |
) |
| Net loss attributable to non-controlling interests |
|
|
— |
|
|
|
— |
|
| |
|
|
|
|
|
|
|
|
| NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS |
|
|
(862,854 |
) |
|
|
(827,756 |
) |
| |
|
|
|
|
|
|
|
|
| OTHER COMPREHENSIVE INCOME |
|
|
|
|
|
|
|
|
| Foreign currency translation income |
|
|
118,739 |
|
|
|
3,586 |
|
| |
|
|
|
|
|
|
|
|
| Total other comprehensive loss |
|
|
118,739 |
|
|
|
3,586 |
|
| COMPREHENSIVE LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS |
|
$ |
(744,115 |
) |
|
$ |
(824,170 |
) |
| |
|
|
|
|
|
|
|
|
| Net loss per share-basic and diluted - basic and diluted |
|
$ |
(0.02 |
) |
|
$ |
(0.01 |
) |
| |
|
|
|
|
|
|
|
|
| Weighted average number of shares outstanding during the year - basic and diluted |
|
|
56,874,850 |
|
|
|
56,874,850 |
|
The accompanying notes are an integral part of these consolidated financial statements
ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Stock
subscriptions
receivable |
|
Additional
paid-in
capital |
|
Deferred
stock
compensation |
|
Accumulated
deficit during
development
stage |
|
Accumulated
other
comprehensive
loss |
|
Non-controlling interests |
|
Total |
|
| |
|
Common stock |
|
Shares to be issued |
|
|
|
|
|
|
|
|
| |
|
Number
of shares |
|
Amount |
|
Number
of shares |
|
Amount |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance at October 31, 2013 |
|
|
56,874,850 |
|
$ |
569 |
|
|
— |
|
$ |
— |
|
$ |
— |
|
$ |
1,907,889 |
|
$ |
— |
|
$ |
(4,572,351 |
) |
$ |
(270,552 |
) |
$ |
— |
|
$ |
(2,934,445 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Imputed interest on advances from directors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,079 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
20,079 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net loss for the year |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(827,756 |
) |
|
— |
|
|
— |
|
|
(827,756 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Foreign currency translation gain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
3,586 |
|
|
— |
|
|
3,586 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance at October 31, 2014 |
|
|
56,874,850 |
|
$ |
569 |
|
|
— |
|
$ |
— |
|
$ |
— |
|
$ |
1,927,968 |
|
$ |
— |
|
$ |
(5,400,107 |
) |
$ |
(266,966 |
) |
$ |
— |
|
$ |
(3,738,536 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Imputed interest on advances from directors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,164 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
21,164 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net loss for the year |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(862,854 |
) |
|
— |
|
|
— |
|
|
(862,854 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Foreign currency translation gain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
118,739 |
|
|
— |
|
|
118,739 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance at October 31, 2015 |
|
|
56,874,850 |
|
$ |
569 |
|
|
— |
|
$ |
— |
|
$ |
— |
|
$ |
1,949,132 |
|
$ |
— |
|
$ |
(6,262,961 |
) |
$ |
(148,227 |
) |
$ |
— |
|
$ |
(4,461,487 |
) |
The accompanying notes are an integral part of these consolidated financial statements
ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
| |
|
|
|
|
|
|
|
|
| |
|
Year ended
October 31, |
|
| |
|
2015 |
|
|
2014 |
|
| CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
| Net loss attributable to ABMT common stockholders |
|
$ |
(862,854 |
) |
|
$ |
(827,756 |
) |
| Adjustments to reconcile net loss to cash used in operating activities: |
|
|
|
|
|
|
|
|
| Depreciation |
|
|
30,451 |
|
|
|
26,640 |
|
| Loss on disposal of property and equipment |
|
|
— |
|
|
|
— |
|
| Stock issued for services |
|
|
— |
|
|
|
— |
|
| Non-controlling interests |
|
|
— |
|
|
|
— |
|
| Imputed interest |
|
|
21,164 |
|
|
|
20,079 |
|
| Changes in operating assets and liabilities |
|
|
|
|
|
|
|
|
| Decrease (increase) in: |
|
|
|
|
|
|
|
|
| Inventories |
|
|
(2,825 |
) |
|
|
— |
|
| Other receivables and prepaid expenses |
|
|
89 |
|
|
|
2,270 |
|
| (Decrease) increase in: |
|
|
|
|
|
|
|
|
| Other payables and accrued expenses |
|
|
(6,418 |
) |
|
|
46,346 |
|
| Net cash used in operating activities |
|
|
(820,393 |
) |
|
|
(732,421 |
) |
| |
|
|
|
|
|
|
|
|
| CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
| Purchase of property and equipment |
|
|
(32,311 |
) |
|
|
(8,793 |
) |
| (Increase) decrease in deposit for purchase of property and equipment |
|
|
15,899 |
|
|
|
(15,009 |
) |
| Net cash used in investing activities |
|
|
(16,412 |
) |
|
|
(23,802 |
) |
| |
|
|
|
|
|
|
|
|
| CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
| Stock issued to founders |
|
|
— |
|
|
|
— |
|
| Proceeds from issuance of shares |
|
|
— |
|
|
|
— |
|
| Contribution by stockholders |
|
|
— |
|
|
|
— |
|
| Distributed to stockholders |
|
|
— |
|
|
|
— |
|
| Due to a stockholder |
|
|
102,959 |
|
|
|
109,253 |
|
| Due to directors |
|
|
50,376 |
|
|
|
(51,460 |
) |
| Due from related parties |
|
|
— |
|
|
|
— |
|
| Due to related parties |
|
|
648,640 |
|
|
|
724,435 |
|
| Net cash provided by financing activities |
|
|
801,975 |
|
|
|
782,228 |
|
| |
|
|
|
|
|
|
|
|
| EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS |
|
|
(1,220 |
) |
|
|
(31 |
) |
| |
|
|
|
|
|
|
|
|
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS |
|
|
(36,050 |
) |
|
|
25,974 |
|
| |
|
|
|
|
|
|
|
|
| CASH AND CASH EQUIVALENTS AT THE BEGINNING OF YEAR |
|
|
74,354 |
|
|
|
48,380 |
|
| |
|
|
|
|
|
|
|
|
| CASH AND CASH EQUIVALENTS AT THE END OF YEAR |
|
$ |
38,304 |
|
|
$ |
74,354 |
|
The accompanying notes are an integral part of these consolidated financial statements
ADVANCED BIOMEDICAL TECHNOLOGIES, INC.
AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
1. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION |
Advanced Biomedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006.
Shenzhen Changhua Biomedical Engineering Co., Ltd. (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the China Food and Drug Administration (“CFDA”, formerly known as “SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities”, is considered a Development Stage Company.
Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on 31 May, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder and 37% by a third party corporation.
On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.
On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.
Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.
On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became a 80.7% stockholder of ABMT.
On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.
The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.
Accordingly, these financial statements include the following:
|
(1) |
The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost. |
|
(2) |
The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction. |
ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).
|
(B) |
Principles of consolidation |
The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.
All significant inter-company balances and transactions have been eliminated in consolidation.
The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
|
(D) |
Cash and cash equivalents |
For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2015 and 2014, all the cash and cash equivalents were denominated in United States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government.
Inventories are stated at the lower of cost, computed using the first-in, first-out method, or market, which represents selling price less cost to sell. If the cost of the inventories exceeds their market value, provisions are made currently for the difference between the cost and the market value.
|
(F) |
Property and equipment |
Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.
Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.
The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Impairment or Disposal of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2015 and 2014, the Company has not recognized any allowances for impairment.
|
(H) |
Fair value of financial instruments |
FASB Codification Topic 825(ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.
The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.
We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.
|
(J) |
Research and development |
Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2015 and 2014 were $60,202 and $47,700 respectively.
|
(K) |
Foreign currency translation |
The reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$ and RMB respectively.
Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.
The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.
The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:
| |
|
October 31, 2015 |
|
October 31, 2014 |
| Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end |
|
US$1=HK$7.7496=RMB6.3180
|
|
US$1=HK$7.7551=RMB6.1124
|
| |
|
|
|
|
|
Amounts included in the statements of operations and cash flows for the year
|
|
US$1=HK$7.7530=RMB6.2425
|
|
US$1=HK$7.7543=RMB6.1498
|
The translation gain recorded for the years ended October 31, 2015 and 2014 were $118,739 and $3,586 respectively.
No presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.
The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in China’s political and economic conditions. Any significant revaluation of RMB may materially affect the Company’s financial condition in terms of US$ reporting.
|
(L) |
Other comprehensive loss |
The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$ is reported as other comprehensive gain or loss in the statements of operations and stockholders’ deficit. Other comprehensive gain for the years ended October 31, 2015 and 2014 were $118,739 and $3,586 respectively.
Basic loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There are no potentially dilutive securities as at October 31, 2015 and October 31, 2014.
The Company operates in only one segment, thereafter segment disclosure is not presented.
|
(O) |
Recent Accounting Pronouncements |
In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Accounting Standards Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met conditions which would subject these financial statements for additional disclosure.
Inventories as at October 31, 2015 and 2014 consisted of the followings:
| |
|
October 31, |
|
| |
|
2015 |
|
|
2014 |
|
| |
|
|
|
|
|
|
| Testing reagents |
|
$ |
2,633 |
|
|
$ |
— |
|
| Packing materials |
|
|
158 |
|
|
|
— |
|
| |
|
$ |
2,791 |
|
|
$ |
— |
|
|
3. |
PROPERTY AND EQUIPMENT |
The following is a summary of property and equipment at October 31, 2015 and 2014:
| |
|
October 31, |
|
| |
|
2015 |
|
|
2014 |
|
| |
|
|
|
|
|
|
| Plant and machinery |
|
$ |
294,378 |
|
|
$ |
272,214 |
|
| Motor vehicles |
|
|
43,637 |
|
|
|
45,105 |
|
| Office equipment |
|
|
34,527 |
|
|
|
34,523 |
|
| Computer software |
|
|
5,017 |
|
|
|
5,017 |
|
| Office improvements |
|
|
127,162 |
|
|
|
131,439 |
|
| Construction in progress |
|
|
|
|
|
|
|
|
| |
|
|
504,721 |
|
|
|
488,298 |
|
| Less: accumulated depreciation |
|
|
398,102 |
|
|
|
380,044 |
|
| |
|
|
|
|
|
|
|
|
| Property and equipment, net |
|
$ |
106,619 |
|
|
$ |
108,254 |
|
Depreciation expense for the year ended October 31, 2015 and 2014 was $30,451 and $26,640 respectively.
|
4. |
OTHER PAYABLES AND ACCRUED EXPENSES |
Other payables and accrued expenses at October 31, 2015 and 2014 consisted of the following:
| |
|
|
|
|
|
|
| |
|
October 31, |
|
| |
|
2015 |
|
|
2014 |
|
| |
|
|
|
|
|
|
| Other payables |
|
$ |
40 |
|
|
$ |
929 |
|
| Accrued expenses |
|
|
97,001 |
|
|
|
104,842 |
|
| |
|
$ |
97,041 |
|
|
$ |
105,771 |
|
|
5. |
RELATED PARTY TRANSACTIONS |
As of October 31, 2015 and 2014, the Company owed $562,187 and $459,131 respectively to Titan Technology Development Limited, a stockholder.
As of October 31, 2015 and 2014, advances from related parties were as follows:
| |
|
October 31, |
|
| |
|
2015 |
|
|
2014 |
|
| |
|
|
|
|
|
|
| Chi Fung Yu |
|
$ |
1,807,103 |
|
|
$ |
1,618,333 |
|
| Que Feng |
|
|
33,133 |
|
|
|
— |
|
| Chen Tie Jun |
|
|
1,660,763 |
|
|
|
1,370,405 |
|
| Shenzhen Hygeian Medical Device Co., Ltd. |
|
|
27,229 |
|
|
|
— |
|
| Amount due to related parties |
|
$ |
3,528,228 |
|
|
$ |
2,988,738 |
|
Advances from a stockholder and related parties are unsecured, repayable on demand and bearing interest at 7% per annum. Interest expenses on advances from a stockholder and the related parties accrued for the years ended October 31, 2015 and 2014 were as follows:
| |
|
October 31, |
|
| |
|
2015 |
|
|
2014 |
|
| |
|
|
|
|
|
|
| Titan Technology Development Limited, a stockholder |
|
$ |
31,615 |
|
|
$ |
26,081 |
|
| Related parties: |
|
|
|
|
|
|
|
|
| Que Feng |
|
|
1,495 |
|
|
|
— |
|
| Chi Fung Yu |
|
|
99,978 |
|
|
|
87,351 |
|
| Chen Tie Jun |
|
|
87,089 |
|
|
|
67,961 |
|
| Shenzhen Hygeian Medical Device Co., Ltd. |
|
|
114 |
|
|
|
— |
|
| Interest expenses to a stockholder and related parties |
|
$ |
220,291 |
|
|
$ |
181,393 |
|
As of October 31, 2015 and 2014, advances from directors were as follows:
| |
|
October 31, |
|
| |
|
2015 |
|
|
2014 |
|
| |
|
|
|
|
|
|
| Hui Wang |
|
$ |
417,966 |
|
|
$ |
382,280 |
|
| Chiming Yu |
|
|
21,897 |
|
|
|
20,230 |
|
| Amount due to directors |
|
$ |
439,863 |
|
|
$ |
402,510 |
|
Advances from directors were unsecured, repayable on demand and interest free. Imputed interests on the amounts owed to Hui Wang, a director, were $21,164 and $20,079 for the years ended October 31, 2015, and 2014 respectively.
|
6. |
STOCKHOLDERS’ DEFICIENCY |
On December 8, 2011, the Company issued 100,000 shares of restricted common stock at $0.2 to Dr. John Lynch, the Company’s chief officer of dental technologies, for services for a term of twelve months. The shares were valued at the closing price on the date of grant yielding an aggregate fair value of $20,000, fully recognised in prior years as consultancy fees included in general and administrative expenses.
On 28 October 2013, the Company issued 150,000 shares of restricted common stock as directors’ services compensation for past services to each of Mr. Chi Ming Yu and Kai Gui, directors of the Company. The shares were valued at the closing price of $0.71 per share on the date of grant, yielding an aggregate fair value of $213,000.
|
7. |
COMMITMENTS AND CONTINGENCIES |
The full time employees of the Company are entitled to employee benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a Chinese government mandated multi-employer defined contribution plan. The Company is required to accrue for these benefits based on certain percentages of the employees’ salaries and make contributions to the plans out of the amounts accrued for medical and pension benefits. The total provisions and contributions made for such employee benefits was $75,813 and $74,189 for the years ended October 31, 2015 and 2014 respectively. The Chinese government is responsible for the medical benefits and the pension liability to be paid to these employees.
The Company leased from third parties office space, a staff canteen and an apartment for a director at monthly rent prevailing at October 31, 2015 of $2,060, $135 and $1,266 (2014: $2,348, Nil and $1,309) respectively. All of these operating leases expired on July 20, 2015, Jul 1, 2015 and June 30, 2014 respectively. The Company continues to lease these premises at same monthly rent pending a formal renewal of these leases.
The Company also leases five apartments (2014: eight apartments and a staff canteen) for staff under two operating leases (2014: three leases) from third parties at monthly rental totaling $475 (2014: $965), both of which will expire in July 2015.
As of October 31, 2015, the Company had outstanding commitments with respect to the above operating leases, which are due as follows:
| |
|
|
|
|
|
| 2016 |
|
|
|
4,856 |
|
| 2017 |
|
|
|
— |
|
| Total |
|
|
$ |
4,856 |
|
The Company has no outstanding commitments contracted for, net of deposit paid, in respect of acquisitions of plant and machineries as of October 31, 2015 (2014: $16,237).
ABMT was incorporated in the United States and has incurred net operating loss for income tax purposes for 2015 and 2014. ABMT has net operating loss carry forwards for income taxes amounting to approximately $1,612,970 and $1,512,723 as of October 31, 2015 and 2014 respectively which may be available to reduce future years’ taxable income. These carry forwards, will expire, if not utilized, commencing in 2029. Management believes that the realization of the benefits from these losses appears uncertain due to the Company’s limited operating history and continuing losses. Accordingly, a full, deferred tax asset valuation allowance has been provided and no deferred tax asset valuation allowance has been provided and no deferred tax asset benefit has been recorded. The valuation allowance at October 31, 2015 and 2014 was $548,410 and $514,326 respectively. The net change in the valuation allowance for 2015 was an increase of $34,084.
Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.
Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been 25%. No income tax expense has been provided by Shenzhen Changhua as it has incurred losses. The losses cannot be carried forward as Shenzhen Changhua has not yet commenced operation.
|
9. |
CONCENTRATIONS AND RISKS |
As at October 31, 2015, 94% and 6% of the Company’s assets were located in the P.R.C. and the United States respectively.
As at October 31, 2014, 91% and 9% of the Company’s assets were located in the P.R.C. and the United States respectively.
As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $6,262,961 as of October 31, 2015 that includes a net loss of $862,854 for the year ended October 31, 2015. The Company’s total current liabilities exceed its total current assets by $4,568,106 and the Company used cash in operations of $820,393. These factors raise substantial doubt about its ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
To continue as a going concern, the Company is actively pursuing additional funding and strategic partners to enable it to implement its business plan. Management believes that these actions, if successful, will allow the Company to continue its operations through the next fiscal year.
The Company has evaluated the existence of significant events subsequent to the balance sheet date through the date the financial statements were issued and has determined that there were no subsequent events or transactions which would require recognition or disclosure in the financial statements other than stated below:
On [13 November 2015], the Company has entered into a Debt Conversion Agreement with a stockholder to convert $500,000 of the accrued interest, payable to the Company’s the stockholder and its shareholders, into 10,000,000 shares (“The Conversion Shares”) of common stock at a conversion price of $0.05 per share. Should the Conversion Shares have been issued as at October 31, 2015, the loss per share for the year ended October 31, 2015 would be US$0.01.
| ITEM 9. |
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE. |
There were no disagreements related to accounting principles or practices, financial statement disclosure, internal controls or auditing scope or procedure during the two fiscal years and interim periods, including the interim period up through the date the relationship ended.
| ITEM 9A. |
CONTROLS AND PROCEDURES. |
Evaluation of Disclosure Controls and Procedures
We have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Our disclosure controls and procedures are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our principal executive officer and principal financial officer by others within our organization. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of October 31, 2015 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of October 31, 2015.
Management’s Annual Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of October 31, 2015, based on the criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission (1992). Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of October 31, 2015. The Company’s internal control over financial reporting as of October 31, 2015 has not been audited by the Company’s independent accountants.
Changes in Internal Control Over Financial Reporting
During the year ended October 31, 2015, there were no significant changes in our internal control over financial reporting that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.
| ITEM 9B. |
OTHER INFORMATION |
None.
| ITEM 10. |
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE |
Officers and Directors
Our directors serve until his successor is elected and qualified. Each of our officers is elected by the board of directors to a term of one (1) year and serves until his or her successor is duly elected and qualified, or until he or she is removed from office. The board of directors has no nominating, auditing or compensation committees.
The name, age and position of our officers and directors are set forth below:
| Name and Address |
Age |
Position(s) |
| Chi Ming Yu |
42 |
President, Director |
| Hui Wang |
46 |
Chief Executive Officer, Director |
| Kai Gui |
46 |
Director, Secretary, Chief Financial Officer |
The person named above has held his offices/positions since inception of our company and is expected to hold his offices/positions until the next annual meeting of our stockholders.
Background of our Officers and Directors
Chi Ming Yu, Director and President, is Director of Operations at Titan Holdings, Inc. where his main responsibilities are in Administration, Company Finance and Investment, Marketing Research and Customer Relationship. From 2000 to 2003, Mr. Yu worked as a sales manager at Fu Feng LLC. From 2003 to present, Mr. Yu worked as Vice President at Titan Technology Development Ltd. Mr. Yu studied Computer Science at Rutgers University, New Jersey. Mr. Yu has extensive knowledge of the Company’s product line, and is fluent in several languages, including English and Chinese. The Board concluded that Mr. Yu should serve as a Director due to his background in the Company’s product line together with his communication skills
Hui Wang, Director and Chief Executive Officer, started her career at Hainan Xinte Pharmaceutical Ltd in China in 1990. She worked her way up from cashier to sales representative and then to sales manager. She then worked as District Manager of Southern China with Hainan Tianfeng Pharmaceutical Ltd, from 1995 to 2000 and as General Manager with Hainan Yichen Pharmaceutical Ltd. from 2001 to 2004. She is now the General Manager of Shenzhen Changhua. Ms Wang has skills and experience in R&A, marketing and business development in Chinese medical industry. The Board concluded that Hui Wang should serve as a Director due to her skills and experience in pharmaceutical sales and business development.
Kai Gui, Director, Secretary and Chief Financial Officer, worked as an Analyst Programmer in the British media industry, and as IT Manager, Circulation Manager, and Foreign Publishing Director at S.J.P. Ltd in London from 1994 to 2008. Beginning in 2000 Mr. Gui participated in several business projects involving Chinese publicly listed companies. He is the Director of China Feed Industry Association Information Centre’s European Office and Vice President of Titan Technology Development Ltd. After graduating from the University of Westminster in London, Mr. Gui took a Post-graduate course in Financial Management at Middlesex University in London. The Board concluded that Kai Gui should serve as a Director due to his business experience and financial management skills.
Involvement in Certain Legal Proceedings
To the best of our knowledge, none of our directors or executive officers, during the past ten years, has been involved in any legal proceeding of the type required to be disclosed under applicable SEC rules, including:
| |
1. |
Any petition under the Federal bankruptcy laws or any state insolvency law being filed by or against, or a receiver, fiscal agent or similar officer being appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;
|
| |
2. |
Conviction in a criminal proceeding, or being a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);
|
| |
|
|
|
| |
3. |
Being the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities: |
| |
|
|
|
| |
|
i. |
Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity; |
| |
|
|
|
| |
|
ii. |
Engaging in any type of business practice; or |
| |
|
|
|
| |
|
iii. |
Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws; |
| |
|
|
|
| |
4. |
Being the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (3)(i) of this section, or to be associated with persons engaged in any such activity; |
| |
|
|
| |
5. |
Being found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated; |
| |
|
|
| |
6. |
Being found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated; |
| |
|
|
| |
7. |
Being the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of: |
| |
|
|
| |
|
i. |
Any Federal or State securities or commodities law or regulation; or |
| |
|
|
|
| |
|
|
|
| |
|
ii. |
Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or |
| |
|
|
|
| |
|
iii. |
Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or |
| |
|
|
|
| |
8. |
Being the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member. |
Audit Committee and Charter
We have a separately-designated audit committee of the board. Our board of directors performs audit committee functions. None of our directors are deemed independent. All directors also hold positions as our officers. Our audit committee is responsible for: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; (3) establishing procedures for the confidential, anonymous submission by our employees of concerns regarding accounting and auditing matters; (4) engaging outside advisors; and, (5) funding for the outside auditory and any outside advisors engagement by the audit committee. A copy of our audit committee charter is filed as an exhibit to this report.
Audit Committee Financial Expert
None of our directors or officers has the qualifications or experience to be considered a financial expert. We believe the cost related to retaining a financial expert at this time is prohibitive. Further, because of our limited operations, we believe the services of a financial expert are not warranted.
Code of Ethics
We have adopted a corporate code of ethics. We believe our code of ethics is reasonably designed to deter wrongdoing and promote honest and ethical conduct; provide full, fair, accurate, timely and understandable disclosure in public reports; comply with applicable laws; ensure prompt internal reporting of code violations; and provide accountability for adherence to the code. A copy of the code of ethics is filed as an exhibit to this report.
Disclosure Committee and Charter
We have a disclosure committee and disclosure committee charter. Our disclosure committee is comprised of all of our officers and directors. The purpose of the committee is to provide assistance to the Chief Executive Officer and the Chief Financial Officer in fulfilling their responsibilities regarding the identification and disclosure of material information about us and the accuracy, completeness and timeliness of our financial reports. A copy of the disclosure committee charter is filed as an exhibit to this report.
| ITEM 11. |
EXECUTIVE COMPENSATION |
The following table sets forth information with respect to compensation paid by the registrant to its officers during the last completed fiscal year ended October 31, 2015.
| Executive Officer Compensation Table |
|
Name
(a) |
|
Fees
Earned
or
Paid in
Cash
(US$)
(b) |
|
|
Stock
Awards
(US$)
(c) |
|
|
Option
Awards
(US$)
(d) |
|
|
Non-Equity
Incentive Plan
Compensation
(US$)
(e) |
|
|
Nonqualified
Deferred
Compensation
Earnings
(US$)
(f) |
|
|
All Other
Compensation
(US$)
(g) |
|
|
Total
(US$)
(h) |
|
| |
|
| Hui Wang |
|
$ |
37,600 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
$ |
37,600 |
|
| Chi Ming Yu |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
| Kai Gui |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
The following table sets forth information with respect to compensation paid by the registrant to its directors during the last completed fiscal year ended October 31, 2015.
| Director Compensation |
|
Name
(a) |
|
Fees
Earned
or
Paid in
Cash
(US$)
(b) |
|
|
Stock
Awards
(US$)
(c) |
|
|
Option
Awards
(US$)
(d) |
|
|
Non-Equity
Incentive Plan
Compensation
(US$)
(e) |
|
|
Nonqualified
Deferred
Compensation
Earnings
(US$)
(f) |
|
|
All Other
Compensation
(US$)
(g) |
|
|
Total
(US$)
(h) |
|
| |
|
| Hui Wang |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
| Chi Ming Yu |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
| Kai Gui |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
All compensation received by our officers and directors has been disclosed.
There are no stock option, retirement, pension, or profit sharing plans for the benefit of our officers and directors.
Long-Term Incentive Plan Awards
We do not have any long-term incentive plans that provide compensation intended to serve as incentive for performance.
Indemnification
Under our Bylaws, we may indemnify an officer or director who is made a party to any proceeding, including a lawsuit, because of his position, if he acted in good faith and in a manner he reasonably believed to be in our best interest. We may advance expenses incurred in defending a proceeding. To the extent that the officer or director is successful on the merits in a proceeding as to which he is to be indemnified, we must indemnify him against all expenses incurred, including attorney’s fees. With respect to a derivative action, indemnity may be made only for expenses actually and reasonably incurred in defending the proceeding, and if the officer or director is judged liable, only by a court order. The indemnification is intended to be to the fullest extent permitted by the laws of the State of Nevada.
Regarding indemnification for liabilities arising under the Securities Act of 1933, which may be permitted to directors or officers under Nevada law, we are informed that, in the opinion of the Securities and Exchange Commission, indemnification is against public policy, as expressed in the Act and is, therefore, unenforceable.
| ITEM 12. |
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS |
The registrant has no compensation plans (including individual compensation arrangements) under which equity securities of the registrant are authorized for issuance.
The following table sets forth, as of the date of this Annual Report on Form 10-K, the total number of shares owned beneficially by each of our directors, officers and key employees, individually and as a group, and the present owners of 5% or more of our total outstanding shares. The stockholders listed below have direct ownership of his/her shares and possess voting and dispositive power with respect to the shares.
| (1) Title of Class |
(2) Name and address of beneficial owner |
|
(3) Amount
and nature
of beneficial ownership |
|
|
(4) Percent
of class |
|
| Common Stock |
Hui Wang, CEO & Director |
|
|
22,153,540 |
|
|
|
33.127 |
% |
| Common Stock |
Chi Ming Yu, President & Director |
|
|
150,000 |
|
|
|
0.224 |
% |
| Common Stock |
Kai Gui, Secretary & Director |
|
|
300,000 |
|
|
|
0.449 |
% |
| Common Stock |
Titan Technology Development, LTD.,
Room 1903 Hing Yip, Commercial Centre, 272
Des Voeux Road Central, Hong Kong, 718332
|
|
|
25,054,881 |
|
|
|
37.465 |
% |
| Common Stock |
WU Ai Ping, Room 802, 35 Weicheng Street,
Hongyun Garden, Zhongtangshi Lane, Huangpu
Road, Tianhe, Guangzhou, 510655 |
|
|
5,000,000 |
|
|
|
7.477 |
% |
| All Officers & Directors |
|
|
|
22,603,540 |
|
|
|
33.8 |
% |
| ITEM 13. |
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE |
Kai Gui, officer and director of Registrant owns five percent (5%) of the outstanding capital stock of Titan Technology Development, LTD., and Chi Fung Yu, brother of Registrant’s president Chi Ming Yu, owns seventy percent (70%) of the outstanding capital stock of Titan Technology Development, LTD.
As of October 31, 2015 and 2014, the Company owed $562,187 and $459,131 respectively to a stockholder - Titan Technology Development Ltd., which is unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed. An agreement between Titan Technology Development Ltd. and the Registrant for a loan in the amount of $480,000 is included as an exhibit to this Form 10-K. There is no formal written agreement between Titan Technology Development Ltd. and the Registrant for the balance of funds owed to Titan Technology Development Ltd.
As of October 31, 2015 and 2014, the Company owed $1,807,103 and $1,618,333 to Chi Fung Yu, $1,660,763 and $1,370,405 to Tie Jun Chen, $33,133 and $0 to Que Feng (related parties), which are unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed. There is no formal written agreement between the Company and Chi Fung Yu, Tie Jun Chen or Que Feng. Chi Fung Yu and Tie Jun Chen are directors of Titan Technology Development Ltd. (TTD), and have been lending money to Shenzhen Changhua on behalf of TTD. Que Feng is a director of Shenzhen Changhua, a subsidiary of the Company.
As of October 31, 2015 and 2014, the Company owed the following amounts respectively to two directors for advances made - $417,966 and $382,280 to Hui Wang, $21,897 and $20,230 to Chi Ming Yu. These advances were made on an unsecured basis, repayable on demand and interest free.
Total interest expenses on advances from a stockholder accrued for the year ended October 31, 2015 and 2014 are $31,615 and $26,081 for Titan Technology Development Limited.
Total interest expenses on advances from following related parties accrued for the year ended October 31, 2015 and 2014 are $99,978 and $87,351 for Chi Fung Yu; $87,089 and $67,961 for Tie Jun Chen; $1,495 and $0 for Que Feng.
Imputed interest charged at 5% per annum on the amounts owed to two directors for the year ended October 31, 2015 and 2014 respectively is $21,164 and $20,079 for Hui Wang; $0 and $0 for Chi Ming Yu.
| ITEM 14. |
PRINCIPAL ACCOUNTING FEES AND SERVICES |
(1) Audit Fees
The aggregate fees billed for each of the last two fiscal years for professional services rendered by the principal accountant for our audit of annual financial statements and review of financial statements included in our Form 10-Qs or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years was:
| 2015 |
|
$ |
20,000 |
|
AWC (CPA) Limited |
| 2015 |
|
$ |
40,439 |
|
Baker Tilly Hong Kong Limited |
| 2014 |
|
$ |
32,650 |
|
Baker Tilly Hong Kong Limited |
(2) Audit-Related Fees
There is no fee billed in each of the last two fiscal years for assurance and related services by the principal accountants that are reasonably related to the performance of the audit or review of our financial statements and are not reported in the preceding paragraph.
(3) Tax Fees
There is no fee billed in each of the last two fiscal years for professional services rendered by the principal accountant for tax compliance, tax advice, and tax planning.
(4) All Other Fees
There is no fee billed in each of the last two fiscal years for the products and services provided by the principal accountant, other than the services reported in paragraphs (1), (2), and (3).
(5) Our audit committee’s pre-approval policies and procedures described in paragraph (c)(7)(i) of Rule 2-01 of Regulation S-X were that the audit committee pre-approves all accounting related activities prior to the performance of any services by any accountant or auditor.
(6) There is no hour expended on the principal accountant’s engagement to audit our financial statements for the most recent fiscal year that were attributed to work performed by persons other than the principal accountant’s full time and permanent employees was.
| ITEM 15. |
EXHIBITS, FINANCIAL STATEMENT SCHEDULES |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
ADVANCED BIOMEDICAL TECHNOLOGIES, INC.
| Signature |
Title |
Date |
| |
|
|
| /s/Chi Ming Yu |
President and Director |
February 16, 2016 |
| Chi Ming Yu |
(Principal Executive Officer) |
|
| |
|
|
| /s/Kai Gui |
Director, Secretary and Chief Financial Officer |
February 16, 2016 |
| Kai Gui |
(Principal Financial Officer) |
|
| |
|
|
| /s/Hui Wang |
Director and Chief Executive Officer |
February 16, 2016 |
| Hui Wang |
(Controller) |
|
Advanced Biomedical Technologies Inc. 10-K
Exhibit
10.1
Loan
Agreement
TTD/ABMT/L1510-01
| Lender: | TITAN
TECHNOLOGY DEVELOPMENT LIMITED |
| Address: | 1903
HING YIP COMMERCIAL CENTRE, 272 DES VOEUX ROAD CENTRAL, HONG KONG. |
| | (Hong
Kong Company Registration No.: 718332) |
| Borrower: | ADVANCED
BIOMEDICAL TECHNOLOGIES, INC. |
| Address: | 350
FIFTH AVE., 59TH FLOOR, NEW YORK, NY 10118 |
| | USA
(Incorporated in the State of Nevada, USA) |
Borrower
is the controlling shareholder of Shenzhen Changhua Biomedical Engineering Co. Ltd., approved by Shenzhen Bureau of Trade and
Industry’s permit, February 25, 2008 (2008) No. 0539 and Guangdong Shenzhen Joint Venture Permit (2008) No. 0008. Shenzhen
Changhua Biomedical Engineering Co., Ltd. is a company engaged in research and development and production of biodegradable medical
materials. Lender is a major shareholder of Borrower.
| 1) | Loan: |
| | |
| | Lender
agrees to advance to Borrower’s subsidiary Shenzhen Changhua Biomedical Engineering Co., Ltd. (Changhua) the total amount
of USD480,000 - (Four Hundred and Eighty Thousand US dollars). |
| | |
| | Borrower
accepts that Lender may send the total amount in several advances using different financial institutions, associated companies
or individuals that is appointed by Lender. |
| 2) | Use
of Proceed: For Changhua’s R&D, Clinical Trial, GMP Facilities Upgrading and Operation Expenses. |
| 3) | Interest
Rate: Annual interest rate is seven percent (7%). |
| 4) | Loan
Repayment period: 12 months |
| 5) | Repayment: |
| | |
| | Debt
maturity: after 12 months, Borrower will repay Lender the total amount of loan plus interest. |
| | |
| | Outstanding
loan: after 6 months, Lender may demand the return of part of the loan plus interest occurred. |
| 6) | Repayment
Methods and Repayment Source |
| | |
| | Repayment
Methods: cash or securities; |
| | |
| | Repayment
Source: banks and securities firms. |
| 7) | Warranty: |
| | |
| | Borrower
and its subsidiary guarantee that the loan will be used for the purposes stipulated in this agreement and the fund may not be
used for other purposes or illegal activities;
Borrower will return the loan within the terms stipulated in this agreement;
Borrower
and its subsidiary agree to accept the supervision of Lender on the use of proceed provided under this agreement. |
| 8) | Miscellaneous |
| | |
| | This
Agreement may not be amended or modified except by a writing executed by each of the
parties. Neither party shall assign (including the engagement of subcontractors) any
of its rights or obligations under this Agreement without the prior written consent of
the other party. The provisions of this Agreement, including without limitation the obligation
to make loan and interest repayments, shall be binding on Borrower, its Parent Company,
its successors and assigns. All terms of this Agreement, which by their nature extend
beyond its termination, shall remain in effect until fulfilled, and shall apply to the
respective successors and assigns of the parties; |
| | |
| | This
Agreement, including all controversies arising from or relating to performance under this Agreement, shall be governed by and
construed in accordance with the laws of Hong Kong, China. Venue for any action or dispute arising from or relating to this Agreement
shall conclusively lie in the Courts located in Hong Kong, China. Each party hereby waives any objection that it may have based
upon lack of personal jurisdiction, improper venue or forum non conveniens. |
| |
|
|
| Lender: TITAN
TECHNOLOGY DEVELOPMENT LIMITED |
| Signature: |
/s/ Chi Fung YU |
|
| Name and Title: |
Chi Fung YU, Chairman |
|
|
|
|
| Borrower: ADVANCED
BIOMEDICAL TECHNOLOGIES, INC. |
| Signature: |
/s/
Hui Wang |
|
| Name and Title: |
Hui Wang, Director and Chief Executive Officer |
|
| |
| Date: October
31, 2015 |
Advanced Biomedical Technologies Inc. 10-K
Exhibit
14.1
ADVANCED
BIOMEDICAL TECHNOLOGIES INC
CODE OF ETHICS
TOPICS
| |
1. |
Statement of Policy |
| |
2. |
Implementation and Enforcement |
| |
3. |
Relations with Competitors and Other Third Parties |
| |
4. |
Insider Trading, Securities Compliance and Public Statements |
| |
5. |
Financial Reporting |
| |
6. |
Human Resources |
| |
7. |
Environmental, Health and Safety |
| |
8. |
Conflicts of Interest |
| |
9. |
International Trade |
| |
10. |
Government Relations |
| |
11. |
Contractors, Consultants, and Temporary Workers |
| |
12. |
Conclusion |
1.
STATEMENT OF POLICY
The
Company has adopted eight Corporate Values (Focus, Respect, Excellence, Accountability, Teamwork, Integrity, Very Open Communications
and Enjoying Our Work) to provide a framework for all employees in conducting ourselves in our jobs. These policies are not intended
to substitute for those Values, but will serve as guidelines in helping you to conduct the Company’s business in accordance
with our Values. Compliance requires meeting the spirit, as well as the literal meaning, of the law, the policies and the Values.
It is expected that you will use common sense, good judgment, high ethical standards and integrity in all your business dealings.
If
you encounter a situation you are not able to resolve by reference to these policies, ask for help. Contact Chi Ming Yu, President
and Director, who has been identified as responsible for overseeing compliance with these policies.
Violations
of the law or the Company’s policies will subject employees to disciplinary action, up to and including termination of employment.
In addition, individuals involved may subject themselves and the Company to severe penalties including fines and possible imprisonment.
Compliance with the law and high ethical standards in the conduct of Company business should be a top priority for each employee,
officer and director.
2.
IMPLEMENTATION AND ENFORCEMENT
Chi
Ming Yu, our President and Director, has been appointed as Compliance Officer of the Company, responsible for overseeing compliance
with, and enforcement of, all Company policies.
Employees
are expected to be familiar with these policies as they apply to their duties. They should consult with their managers if they
need assistance in understanding or interpreting these policies. Each employee is required to follow these policies and to comply
with their terms. A refusal by any employee to agree to be bound by these policies shall be grounds for discipline up to and including
dismissal.
Any
employee who, in good faith, has reason to believe a Company operation or activity is in violation of the law or of these policies
must call the matter to the attention of Chi Ming Yu, our President and Director. All reports will be reviewed and investigated
and as necessary under the circumstances, and the reporting employee should provide sufficient information to enable a complete
investigation to be undertaken.
Any
employee who makes an allegation in good faith reasonably believing that a person has violated these policies or the law, will
be protected against retaliation.
3.
RELATIONS WITH COMPETITORS AND OTHER THIRD PARTIES
The
Company’s policy is to comply fully with competition and antitrust laws throughout the world. These laws generally prohibit
companies from using illegal means to maintain, obtain or attempt to obtain a monopoly in a market. They also prohibit companies
from engaging in unfair trade practices. “Unfair trade practices” include fixing prices, dividing markets,
agreeing with competitors not to compete, or agreeing to boycott certain customers. It is advised that you consult with Chi Ming
Yu before attending a meeting with a party who may be viewed as a competitor.
4.
INSIDER TRADING, SECURITIES COMPLIANCE AND PUBLIC STATEMENTS
Securities
laws prohibit anyone who is in possession of material, non-public information (“Insider Information”) about a company
from purchasing or selling stock of that company, or communicating the information to others. Information is considered “material”
if a reasonable investor would consider it to be important in making a decision to buy or sell that stock. Some examples include
financial results and projections, new products, acquisitions, major new contracts or alliances prior to the time that they are
publicly announced. Employees who become aware of such Inside Information about the Company must refrain from trading in the shares
of the Company until the Inside Information is publicly announced.
Employees
must also refrain from disclosing that information to persons who do not have a Company need to know, whether they are inside
the Company or outside, such as spouses, relatives or friends.
The
Company makes regular formal disclosures of its financial performance and results of operations to the investment community. We
also regularly issue press releases. Other than those public statements, which go through official Company channels, employees
are prohibited from communicating outside the Company about the Company’s business, financial performance or future prospects.
Such communications include questions from securities analysts, reporters or other news media, but also include seemingly innocent
discussions with family, friends, neighbors or acquaintances.
5.
FINANCIAL REPORTING
The
Company is required to maintain a variety of records for purposes of reporting to the government. The Company requires all employees
to maintain full compliance with applicable laws and regulations requiring that its books of account and records be accurately
maintained. Specifics of these requirements are available from Chi Ming Yu.
6.
HUMAN RESOURCES
The
Company is committed to providing a work environment that is free from unlawful harassment and discrimination, and respects the
dignity of its employees. The Company has policies covering various aspects of its relationship with its employees, as well as
employees’ relationships with each other. For more detailed information, you should consult Chi Ming Yu. Each employee is
expected to be familiar with these policies and to abide by them.
7.
ENVIRONMENTAL, HEALTH AND SAFETY
The
Company is committed to protecting the health and safety of our employees, as well as the environment in general. The Company
expects employees to obey all laws and regulations designed to protect the environment, and the health and safety of our employees,
and to obtain and fully observe all permits necessary to do business.
At
the very least, all employees should be familiar with and comply with safety regulations applicable to their work areas. The Company
will make, to the extent possible, reasonable accommodations for the known physical or mental limitations of our employees. Employees
who require an accommodation should contact Chi Ming Yu. The Company will then engage in an interactive process to determine what
reasonable accommodations may exist.
8.
CONFLICTS OF INTEREST
Each
employee is expected to avoid any activity, investment or association that interferes with the independent exercise of his or
her judgment in the Company’s best interests (“Conflicts of Interest”). Conflicts of Interest can arise in many
situations. They occur most often in cases where the employee or the employee’s family obtains some personal benefit at
the expense of the Company’s best interests.
No
employee, or any member of employee’s immediate family, shall accept money, gifts of other than nominal value, unusual entertainment,
loans, or any other preferential treatment from any customer or supplier of the Company where any obligation may be incurred or
implied on the giver or the receiver or where the intent is to prejudice the recipient in favor of the provider. Likewise, no
employee shall give money, gifts of other than nominal value, unusual entertainment or preferential treatment to any customer
or supplier of the Company, or any employee or family members thereof, where any obligation might be incurred or implied, or where
the intent is to prejudice the recipient in favor of the Company. No such persons shall solicit or accept kickbacks, whether in
the form of money, goods, services or otherwise, as a means of influencing or rewarding any decision or action taken by a foreign
or domestic vendor, customer, business partner, government employee or other person whose position may affect the Company’s
business.
No
employee shall use Company property, services, equipment or business for personal gain or benefit.
Employees
may not: (1) act on behalf of, or own a substantial interest in, any company or firm that does business, or competes, with the
Company; (2) conduct business on behalf of the Company with any company or firm in which the employee or a family member has a
substantial interest or affiliation. Exceptions require advance written approval from the Legal Department.
Employees
should not create the appearance that they are personally benefiting in any outside endeavor as a result of their employment by
the Company, or that the Company is benefiting by reason of their outside interests. Any employee who is not sure whether a proposed
action would present a conflict of interest or appear unethical should consult with Chi Ming Yu.
9.
INTERNATIONAL TRADE
The
Company must comply with a variety of laws around the world regarding its activities. In some cases, the law prohibits the disclosure
of information, whether the disclosure occurs within the U.S. or elsewhere, and whether or not the disclosure is in writing.
Payments
or gifts to non-U.S. government officials are prohibited by law and by Company policy. The Foreign Corrupt Practices Act precludes
payments to non-U.S. government officials for the purpose of obtaining or retaining business, even if the payment is customary
in that country. This law applies anywhere in the world to U.S. citizens, nationals, residents, businesses or employees of U.S.
businesses. Because Advanced Biomedical Technologies Inc. is a U.S. company, this law applies to the Company and all of its subsidiaries.
Any questions on this policy should be directed to Chi Ming Yu.
10.
GOVERNMENT RELATIONS
The
Company is prohibited by law from making any contributions or expenditures in connection with any U.S. national election. This
includes virtually any activity that furnishes something of value to an election campaign for a federal office. Use of the Company’s
name in supporting any political position or ballot measure, or in seeking the assistance of any elected representative, requires
the specific approval of the Chairman and Chief Executive Officer of the Company. Political contributions or expenditures are
not to be made out of Company funds in any foreign country, even if permitted by local law, without the consent of the Company’s
Chairman and Chief Executive Officer.
U.S.
law also prohibits giving, offering, or promising anything of value to any public official in the U.S. or any foreign country
to influence any official act, or to cause an official to commit or omit any act in violation of his or her lawful duty. Company
employees are expected to comply with these laws.
11.
VENDORS, CONTRACTORS, CONSULTANTS AND TEMPORARY WORKERS
Vendors,
contractors, consultants or temporary workers who are acting on the Company’s behalf, or on Company property, are expected
to follow the law, Company policies and honor Company Values. Violations will subject the person or firm to sanctions up to and
including loss of the contract, contracting or consulting agreement, or discharge from temporary assignment.
12.
CONCLUSION
This
Code of Ethics is not intended to cover every possible situation in which you may find yourself. It is meant to give you the boundaries
within which the Company expects you to conduct yourself while representing Advanced Biomedical Technologies Inc. You may find
yourself in a situation where there is no clear guidance given by this Code of Ethics. If that occurs, return to the foundations
stated earlier: common sense, good judgment, high ethical standards and integrity. And refer to the Company’s Values. In
addition, there are many resources upon which you may rely: your management chain, Human Resources, Legal or other Advanced Biomedical
Technologies Inc. departments, and the CEO.
ADVANCED
BIOMEDICAL TECHNOLOGIES INC.
VALUES
FOCUS
We exist only because we are involved in medical device research and manufacturing.
RESPECT
We value all people, treating them with dignity at all times.
EXCELLENCE
We strive for “Best in Class” in everything we do.
ACCOUNTABILITY
We do what we say we will do and expect the same from others.
TEAMWORK
We believe that cooperative action produces superior results.
INTEGRITY
We are honest with ourselves, each other, our customers, our partners and our shareholders.
VERY
OPEN COMMUNICATION We share information, ask for feedback, acknowledge good work, and encourage diverse ideas.
ENJOYING
OUR WORK We work hard, are rewarded for it, and maintain a good sense of perspective, humor and enthusiasm.
Reportable
Violations - Anonymous Reporting Program
Accounting Error
Accounting Omissions
Accounting Misrepresentations
Auditing Matters
Compliance/Regulation Violations
Corporate Scandal
Domestic Violence
Discrimination
Embezzlement
Environmental Damage
Ethics Violation
Fraud
Harassment
Industrial Accidents
Misconduct
Mistreatment
Poor Customer Service
Poor Housekeeping
Sabotage
Securities Violation
Sexual Harassment
Substance Abuse
Theft
Threat of Violence
Unfair Labor Practice
Unsafe Working Conditions
Vandalism
Waste
Waste of Time and Resources
Workplace Violence
Advanced Biomedical Technologies Inc. 10-K
Exhibit 31.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002
I, Hui Wang, certify that:
| 1. | I have reviewed this annual report on Form 10-K of Advanced Biomedical
Technologies Inc.; (the “registrant”); |
| 2. | Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and
cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13(a)-15(e) and 15(d)-15(e))
and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have: |
| a) | designed such disclosure controls and procedures or caused such
disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in
which this report is being prepared; |
| b) | designed such internal controls over financial reporting, or
caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles; |
| c) | evaluated the effectiveness of the registrant’s disclosure
controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls
and procedures as of the end of the period covered by this report based on such evaluation; and |
| d) | disclosed in this report any change in the registrant’s
internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit
committee of registrant’s board of directors (or persons performing the equivalent functions): |
| a) | all significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s
ability to record, process, summarize and report financial information; and |
| b) | any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: February 16, 2016 |
|
| |
By: /s/Hui Wang |
| |
Name: Hui Wang, |
| |
Title: Director and Chief Executive Officer |
|
(Principal Executive Officer) |
Advanced Biomedical Technologies Inc. 10-K
Exhibit 31.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002
I, Kai Gui, certify that:
| 1. | I have reviewed this annual report on Form 10-K of Advanced Biomedical
Technologies Inc.; (the “registrant”); |
| 2. | Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and
cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13(a)-15(e) and 15(d)-15(e))
and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have: |
| a) | designed such disclosure controls and procedures or caused such
disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in
which this report is being prepared; |
| b) | designed such internal controls over financial reporting, or
caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles; |
| c) | evaluated the effectiveness of the registrant’s disclosure
controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls
and procedures as of the end of the period covered by this report based on such evaluation; and |
| d) | disclosed in this report any change in the registrant’s
internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit
committee of registrant’s board of directors (or persons performing the equivalent functions): |
| a) | all significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s
ability to record, process, summarize and report financial information; and |
| b) | any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: February 16, 2016 |
|
|
| |
By: |
/s/Kai Gui |
| |
Name: Kai Gui, |
| |
Title: Director, Secretary and Chief Financial Officer |
Advanced Biomedical Technologies Inc. 10-K
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with
the Annual Report of Advanced Biomedical Technologies Inc. (the “Company”) on Form 10-K for the year ended October
31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “report”), I, Hui Wang, Chief
Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section
13 (a) or 15 (d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in this Report fairly presents, in all material respects, the financial
condition and results of operations of the Company. |
| Dated this 16th day of February, 2016. |
|
| |
|
| /s/ Hui Wang |
|
| Hui Wang |
|
| Director and Chief Executive Officer |
Advanced Biomedical Technologies Inc. 10-K
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with
the Annual Report of Advanced Biomedical Technologies Inc. (the “Company”) on Form 10-K for the year ended October
31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “report”), I, Kai Gui, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and |
| (2) | The information contained in this Report fairly presents, in all material respects, the financial
condition and results of operations of the Company. |
| Dated this 16th day of February, 2016. |
| |
|
| /s/ Kai Gui |
|
| Kai Gui |
|
| Director, Secretary, and Chief Financial Officer |
Advanced Biomedical Technologies Inc. 10-K
Exhibit 99.1
ADVANCED BIOMEDICAL TECHNOLOGIES INC.
CHARTER - AUDIT COMMITTEE
Committee Role
The committee’s
role is to act on behalf of the board of directors and oversee all material aspects of the company’s reporting, control,
and audit functions, except those specifically related to the responsibilities of another standing committee of the board. The
audit committee’s role includes a particular focus on the qualitative aspects of financial reporting to shareholders and
on company processes for the management of business/financial risk and for compliance with significant applicable legal, ethical,
and regulatory requirements.
In addition, the committee
responsible for: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention
and treatment of complaints regarding accounting, internal controls and auditing matters; (3) establishing procedures for the confidential,
anonymous submission by our employees of concerns regarding accounting and auditing matters; (4) establishing internal financial
controls; (5) engaging outside advisors; and, (6) funding for the outside auditor and any outside advisors engagement by the audit
committee.
The role also includes
coordination with other board committees and maintenance of strong, positive working relationships with management, external and
internal auditors, counsel, and other committee advisors.
Committee Membership
The committee shall
consist of the entire board directors. The committee shall have access to its own counsel and other advisors at the committee’s
sole discretion.
Committee Operating Principles
The committee shall fulfill its responsibilities
within the context of the following overriding principles:
| (1) |
Communications - The chairperson and others on the committee shall, to the extent appropriate, have contact throughout the year with senior management, other committee chairpersons, and other key committee advisors, external and internal auditors, etc., as applicable, to strengthen the committee's knowledge of relevant current and prospective business issues. |
| |
|
| (2) |
Committee Education/Orientation - The committee, with management, shall develop and participate in a process for review of important financial and operating topics that present potential significant risk to the company. Additionally, individual committee members are encouraged to participate in relevant and appropriate self-study education to assure understanding of the business and environment in which the company operates. |
| |
|
| (3) |
Annual Plan - The committee, with input from management and other key committee advisors shall develop an annual plan responsive to the “primary committee responsibilities” detailed herein. The annual plan shall be reviewed and approved by the full board. |
| |
|
| (4) |
Meeting Agenda - Committee meeting agendas shall be the responsibility of the committee chairperson, with input from committee members. It is expected that the chairperson would also ask for management and key committee advisors, and perhaps others, to participate in this process. |
| |
|
| (5) |
Committee Expectations and Information Needs - The committee shall communicate committee expectations and the nature, timing, and extent of committee information needs to management, internal audit, and external parties, including external auditors. Written materials. Including key performance indicators and measures related to key business and financial risks shall be received from management, auditors, and others at least one week in advance of meeting dates. Meeting conduct will assume board members have reviewed written materials in sufficient depth to participate in committee/board dialogue. |
| |
|
| (6) |
External Resources -The committee shall be authorized to access internal and external resources, as the committee requires, carrying out its responsibilities. |
| |
|
| (7) |
Committee Meeting Attendees - The committee shall request members of management, counsel, internal audit, and external auditors, as applicable, to participate in committee meetings, as necessary, to carry out the committee responsibilities. Periodically and at least annually, the committee shall meet in private session with only the committee members. It shall be understood that either internal or external auditors, or counsel, may, at any time, request a meeting with the audit committee or committee chairperson with or without management attendance. In any case, the committee shall meet in executive session separately with internal and external auditors, at least annually. |
| |
|
| (8) |
Reporting to the Board of Directors - The committee, through the committee chairperson, shall report periodically, as deemed necessary, but at least semi-annually, to the full board. In addition, summarized minutes from committee meetings, separately identifying monitoring activities from approvals, shall be available to each board member at least one week prior to the subsequent board of directors meeting. |
| |
|
| (9) |
Committee Self Assessment - The committee shall review, discuss, and assess its own performance as well as the committee role and responsibilities, seeking input from senior management, the full board, and others. Changes in role and/or responsibilities, if any, shall be recommended to the full board for approval. |
Meeting Frequency
The committee shall
meet at least three times quarterly. Additional meetings shall be scheduled as considered necessary by the committee or chairperson.
Reporting to Shareholders
The committee shall
make available to shareholders a summary report on the scope of its activities. This may be identical to the report that appears
in the company’s annual report.
Committee’s Relationship with External
and Internal Auditors
| (1) |
The external auditors, in their capacity as independent public accountants, shall be responsible to the board of directors and the audit committee as representatives of the shareholders. |
| (2) |
As the external auditors review financial reports, they will be reporting to the audit committee. They shall report all relevant issues to the committee responsive to agreed-on committee expectations. In executing its oversight role, the board or committee should review the work of external auditors. |
| (3) |
The internal audit function shall be responsible to the board of directors through the committee. |
| (4) |
If either the internal or the external auditors identify significant issues relative to the overall board responsibility that have been communicated to management but, in their judgment, have not been adequately addressed, they should communicate these issues to the committee chairperson. |
| (5) |
Changes in the directors of internal audit or corporate compliance shall be subject to committee approval. |
| |
Primary Committee Responsibilities
Monitor Financial Reporting and Risk
Control Related Matters
The committee should review and assess:
| (1) |
Risk Management - The company’s business risk management process, including the adequacy of the company’s overall control environment and controls in selected areas representing significant financial and business risk. |
| |
| (2) |
Annual Reports and Other Major Regulatory Filings - All major financial reports in advance of filings or distribution. |
| (3) |
Internal Controls and Regulatory Compliance - The company’s system of internal controls for detecting accounting and reporting financial errors, fraud and defalcations, legal violations, and noncompliance with the corporate code of conduct. |
| |
| (4) |
Internal Audit Responsibilities - The annual audit plan and the process used to develop the plan. Status of activities, significant findings, recommendations, and management’s response. |
| |
| (5) |
Regulatory Examinations - SEC inquiries and the results of examinations by other regulatory authorities in terms of important findings, recommendations, and management’s response. |
| |
| (6) |
External Audit Responsibilities - Auditor independence and the overall scope and focus of the annual/interim audit, including the scope and level of involvement with unaudited quarterly or other interim-period information. |
| |
| (7) |
Financial Reporting and Controls - Key financial statement issues and risks, their impact or potential effect on reported financial information, the processes used by management to address such matters, related auditor views, and the basis for audit conclusions. Important conclusions on interim and/or year-end audit work in advance of the public release of financials. |
| |
| (8) |
Auditor Recommendations - Important internal and external auditor recommendations on financial reporting, controls, other matters, and management’s response. The views of management and auditors on the overall quality of annual and interim financial reporting. |
The committee should review, assess, and approve:
| (1) |
The code of ethical conduct. |
| |
| (2) |
Changes in important accounting principles and the application thereof in both interim in and annual financial reports. |
| |
| (3) |
Significant conflicts of interest and related-party transactions. |
| |
| (4) |
External auditor performance and changes in external audit firm (subject to ratification by the full board). |
| |
| (5) |
Internal auditor performance and changes in internal audit leadership and/or key financial management. |
| |
| (6) |
Procedures for whistle blowers. |
| |
| (7) |
Pre-approve allowable services to be provided by the auditor. |
| |
| (8) |
Retention of complaints. |
Advanced Biomedical Technologies Inc. 10-K
Exhibit 99.2
ADVANCED BIOMEDICAL TECHNOLOGIES INC.
DISCLOSURE COMMITTEE
CHARTER
Disclosure Policy
All financial disclosures made by the Corporation
to its security holders or the investment community should (i) be accurate, complete and timely, (ii) fairly present, in all material
respects, the Corporation’s financial condition, results of operations and cash flows, and (iii) meet any other legal, regulatory
or stock exchange requirements.
Committee Purpose
The Corporation’s Disclosure Committee
(the “Committee”) shall assist the Corporation’s officers and directors (collectively, the “Senior Officers”)
fulfilling the Corporation’s and their responsibilities regarding (i) the identification and disclosure of material information
about the Corporation and (ii) the accuracy, completeness and timeliness of the Corporation’s financial reports.
Responsibilities
Subject to the supervision and oversight
of Senior Officers, the Committee shall be responsible for the following tasks:
| · | Review and, as necessary, help revise the Corporation’s controls
and other procedures (“Disclosure Controls and Procedures”) to ensure that (i) information required by the Corporation
to be disclosed to the Securities and Exchange Commission (the “SEC”), and other written information that the Corporation
will disclose to the public is recorded, processed, summarized and reported accurately and on a timely basis, and (ii) such information
is accumulated and communicated to management, including the Senior Officers, as appropriate to allow timely decisions regarding
required disclosure. |
| · | Assist in documenting, and monitoring the integrity and evaluating
the effectiveness of, the Disclosure Controls and Procedures. |
| · | Review the Corporation’s (i) Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q, and Current Reports on Form 8-K, proxy statement, material registration statements, and any other information
filed with the SEC (collectively, the “Reports”), (ii) press releases containing financial information, earnings guidance,
forward-looking statements, information about material transactions, or other information material to the Corporation’s security
holders, (iii) correspondence broadly disseminated to shareholders, and (iv) other relevant communications or presentations (collectively,
the “Disclosure Statements”). |
| · | Discuss information relative to the Committee’s responsibilities
and proceedings, including (i) the preparation of the Disclosure Statements and (ii) the evaluation of the effectiveness of the
Disclosure Controls and Procedures. |
Other Responsibilities
The Committee shall have such other responsibilities,
consistent with the Committee’s purpose, as any Senior Officer may assign to it from time to time.
Disclosure Control Considerations
The Committee shall base the review and revision of the Disclosure
Controls and Procedures on the following factors:
| · | Control Environment: The directives of the Board and Audit
Committee; the integrity and ethical values of the Corporation’s officers and employees, including the “tone at the
top”; the Corporation’s Code of Conduct; and the philosophy and operating style of management, including how employees
are organized and how authority is delegated. |
| · | Risk Assessment: The identification and analysis of relevant
risks to achieving the goal of accurate and timely disclosure, forming a basis for determining how the risks should be managed. |
| · | Control Activities: The procedures to ensure that necessary
actions are taken to address and handle risks to achievement of objectives. |
| · | Information and Communication: The accumulation, delivery
and communication of financial information throughout (i.e., up, down and across) the organization. |
| · | Monitoring: The assessment of the quality of the financial
reporting systems over time through ongoing monitoring and separate evaluations, including through regular management supervision
and reporting of deficiencies upstream. |
Organization
The members of the Committee will be comprised
of the Corporation’s officers and directors.
The Committee may designate two or more
individuals, at least one of whom shall be knowledgeable about financial reporting and another about law, who can, acting together,
review Disclosure Statements when time does not permit full Committee review.
The Senior Officers at their option may,
at any time and from time to time, assume any or all of the responsibilities of the Disclosure Committee identified in this Charter,
including, for example, approving Disclosure Statements when time does not permit the full Committee (or the designated individuals)
to meet or act.
Chair
The Chief Financial Officer of the Corporation
shall act as the Chair of the Committee (unless and until another member of the Committee shall be so appointed by any Senior Officer).
Meetings and Procedures
The Committee shall meet or act as frequently
and as formally or informally as circumstances dictate to (i) ensure the accuracy, completeness and timeliness of the Disclosure
Statements and (ii) evaluate the Disclosure Controls and Procedures and determine whether any changes to the Disclosure Controls
and Procedures are necessary or advisable in connection with the preparation of the Reports or other Disclosure Statements, taking
into account developments since the most recent evaluation, including material changes in the Corporation’s organization
and business lines and any material change in economic or industry conditions.
The Committee shall adopt, whether formally
or informally, such procedures as it deems necessary to facilitate the fulfillment of its responsibilities.
Full Access
The Committee shall have full access to
all of Corporation’s books, records, assets, facilities and personnel, including the internal auditors, in connection with
fulfilling its responsibilities.
Charter Review
The Committee shall review and assess this
Charter annually, and recommend any proposed changes to the Senior Officers for approval.
Interpretation
Any questions of interpretation regarding
this Charter, or the Committee’s responsibilities or procedures, shall be determined initially by the Chair and, to the extent
necessary, ultimately by the Senior Officers.
v3.3.1.900
| X |
- DefinitionIf the value is true, then the document is an amendment to previously-filed/accepted document.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
| Name: |
dei_CurrentFiscalYearEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:gMonthDayItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
| Name: |
dei_DocumentFiscalPeriodFocus |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fiscalPeriodItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
| Name: |
dei_DocumentFiscalYearFocus |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:gYearItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
| Name: |
dei_EntityCommonStockSharesOutstanding |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- DefinitionIndicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
| Name: |
dei_EntityCurrentReportingStatus |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:yesNoItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
| Name: |
dei_EntityFilerCategory |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:filerCategoryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionState aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
| Name: |
dei_EntityPublicFloat |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
| Name: |
dei_EntityVoluntaryFilers |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:yesNoItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
| Name: |
dei_EntityWellKnownSeasonedIssuer |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:yesNoItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
| Name: |
us-gaap_SharePrice |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:perShareItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
v3.3.1.900
CONSOLIDATED BALANCE SHEETS - USD ($)
|
Oct. 31, 2015 |
Oct. 31, 2014 |
| CURRENT ASSETS |
|
|
| Cash and cash equivalents |
$ 38,304
|
$ 74,354
|
| Inventories |
2,791
|
|
| Other receivables and prepaid expenses |
18,118
|
18,768
|
| Total Current Assets |
59,213
|
93,122
|
| Property and equipment, cost |
504,721
|
488,298
|
| Less: Accumulated depreciation |
(398,102)
|
(380,044)
|
| PROPERTY AND EQUIPMENT, NET |
106,619
|
108,254
|
| DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT |
|
16,238
|
| TOTAL ASSETS |
165,832
|
217,614
|
| CURRENT LIABILITIES |
|
|
| Other payables and accrued expenses |
97,041
|
105,771
|
| Due to directors |
439,863
|
402,510
|
| Due to a stockholder |
562,187
|
459,131
|
| Due to related parties |
3,528,228
|
2,988,738
|
| Total Current Liabilities |
$ 4,627,319
|
$ 3,956,150
|
| COMMITMENTS AND CONTINGENCIES |
|
|
| STOCKHOLDERS' DEFICIT |
|
|
| Common stock, $0.00001 par value, 100,000,000 shares authorized, 56,874,850 shares issued and outstanding as of October 31, 2015 and October 31, 2014 |
$ 569
|
$ 569
|
| Additional paid-in capital |
1,949,132
|
1,927,968
|
| Accumulated deficit |
(6,262,961)
|
(5,400,107)
|
| Accumulated other comprehensive loss |
(148,227)
|
(266,966)
|
| Total Deficit |
(4,461,487)
|
(3,738,536)
|
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT |
$ 165,832
|
$ 217,614
|
| X |
- DefinitionInterest owed to directors and related company
| Name: |
abtbi_DepositForPurchasePropertyEquipment |
| Namespace Prefix: |
abtbi_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionCarrying amount as of the balance sheet date of obligations due stockholders. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
| Name: |
abtbi_DueToDirectors |
| Namespace Prefix: |
abtbi_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionAccumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
| Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.30(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5
| Name: |
us-gaap_AdditionalPaidInCapital |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.18)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 12
-Article 7
| Name: |
us-gaap_Assets |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
| Name: |
us-gaap_AssetsCurrent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- References
+ Details
| Name: |
us-gaap_AssetsCurrentAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_CommitmentsAndContingencies |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
| Name: |
us-gaap_CommonStockValue |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionAmounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 12
-Subparagraph a(1)
-Article 6
| Name: |
us-gaap_DueToOfficersOrStockholdersCurrent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
| Name: |
us-gaap_InventoryNet |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.32)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 25
-Article 7
| Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_LiabilitiesCurrent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- References
+ Details
| Name: |
us-gaap_LiabilitiesCurrentAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
| Name: |
us-gaap_OtherLiabilitiesCurrent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=51662447&loc=d3e5879-108316
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Assets
-URI http://asc.fasb.org/extlink&oid=6509628
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
| Name: |
us-gaap_PrepaidExpenseCurrent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_PropertyPlantAndEquipmentGross |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph a
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 8
-Article 7
| Name: |
us-gaap_PropertyPlantAndEquipmentNet |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
| Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E
| Name: |
us-gaap_StockholdersEquity |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- References
+ Details
| Name: |
us-gaap_StockholdersEquityAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
|
Oct. 31, 2015 |
Oct. 31, 2014 |
| Statement of Financial Position [Abstract] |
|
|
| Common Stock Shares Par Value |
$ 0.00001
|
$ 0.00001
|
| Common Stock Shares Authorized |
100,000,000
|
100,000,000
|
| Common Stock Shares Issued |
56,874,850
|
56,874,850
|
| X |
- DefinitionFace amount or stated value per share of common stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
| Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:perShareItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
| Name: |
us-gaap_CommonStockSharesAuthorized |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
| Name: |
us-gaap_CommonStockSharesIssued |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- References
+ Details
| Name: |
us-gaap_StatementOfFinancialPositionAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
|
12 Months Ended |
Oct. 31, 2015 |
Oct. 31, 2014 |
| OPERATING EXPENSES |
|
|
| General and administrative expenses |
$ 514,540
|
$ 543,414
|
| Depreciation |
30,451
|
26,640
|
| Research and development |
60,202
|
47,700
|
| Total Operating Expenses |
605,193
|
617,754
|
| LOSS FROM OPERATIONS |
(605,193)
|
(617,754)
|
| OTHER (EXPENSES) INCOME |
|
|
| Interest income |
119
|
137
|
| Interest paid to a stockholder and related parties |
(220,291)
|
(181,393)
|
| Imputed interest |
(21,164)
|
(20,079)
|
| Other, net |
(16,325)
|
(8,667)
|
| Total Other (Expenses) Income, net |
(257,661)
|
(210,002)
|
| LOSS BEFORE TAXES |
(862,854)
|
(827,756)
|
| NET LOSS |
(862,854)
|
(827,756)
|
| NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS |
(862,854)
|
(827,756)
|
| OTHER COMPREHENSIVE INCOME |
|
|
| Foreign currency translation income |
118,739
|
3,586
|
| Total other comprehensive loss |
118,739
|
3,586
|
| COMPREHENSIVE LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS |
$ (744,115)
|
$ (824,170)
|
| Net loss per share-basic and diluted |
$ (0.02)
|
$ (0.01)
|
| Weighted average number of shares outstanding during the year - basic and diluted |
56,874,850
|
56,874,850
|
| X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831223
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255
| Name: |
us-gaap_ComprehensiveIncomeNetOfTax |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- References
+ Details
| Name: |
us-gaap_ComprehensiveIncomeNetOfTaxAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
| Name: |
us-gaap_Depreciation |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
| Name: |
us-gaap_EarningsPerShareBasicAndDiluted |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:perShareItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
| Name: |
us-gaap_GeneralAndAdministrativeExpense |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
| Name: |
us-gaap_InterestExpenseDebt |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionInterest expense on all other items not previously classified. For example, includes dividends associated with redeemable preferred stock of a subsidiary that is treated as a liability in the parent's consolidated balance sheet. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph -4
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
| Name: |
us-gaap_InterestExpenseOther |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
| Name: |
us-gaap_InvestmentIncomeInterest |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
| Name: |
us-gaap_NetIncomeLoss |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
| Name: |
us-gaap_OperatingExpenses |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- References
+ Details
| Name: |
us-gaap_OperatingExpensesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
| Name: |
us-gaap_OperatingIncomeLoss |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569643-111683
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683
| Name: |
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669625-108580
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=51821188&loc=d3e1436-108581
| Name: |
us-gaap_OtherComprehensiveIncomeLossNetOfTax |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- References
+ Details
| Name: |
us-gaap_OtherIncomeAndExpensesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
| Name: |
us-gaap_OtherNonoperatingExpense |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionThe net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.
| Name: |
us-gaap_OtherOperatingIncomeExpenseNet |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686
| Name: |
us-gaap_ProfitLoss |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
| Name: |
us-gaap_ResearchAndDevelopmentExpense |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
| Name: |
us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY - USD ($)
|
12 Months Ended |
Oct. 31, 2015 |
Oct. 31, 2014 |
| Common stock |
|
|
| Beginning balance |
$ 569
|
$ 569
|
| Beginning balance, shares |
56,874,850
|
56,874,850
|
| Ending balance |
$ 569
|
$ 569
|
| Ending balance, shares |
56,874,850
|
56,874,850
|
| Additional paid-in capital |
|
|
| Beginning balance |
$ 1,927,968
|
$ 1,907,889
|
| Imputed interest on advances from directors |
21,164
|
20,079
|
| Ending balance |
1,949,132
|
1,927,968
|
| Accumulated deficit during the development stage |
|
|
| Beginning balance |
(5,400,107)
|
(4,572,351)
|
| Net loss |
(862,854)
|
(827,756)
|
| Ending balance |
(6,262,961)
|
(5,400,107)
|
| Accumulated other comprehensive loss |
|
|
| Beginning balance |
(266,966)
|
(270,552)
|
| Foreign currency translation gain |
118,739
|
3,586
|
| Ending balance |
(148,227)
|
(266,966)
|
| Beginning balance |
(3,738,536)
|
(2,934,445)
|
| Imputed interest on advances from directors |
21,164
|
20,079
|
| Net loss |
(862,854)
|
(827,756)
|
| Foreign currency translation gain |
118,739
|
3,586
|
| Ending balance |
$ (4,461,487)
|
$ (3,738,536)
|
| X |
- DefinitionAmount of other increase (decrease) in additional paid in capital (APIC).
| Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalOther |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
| Name: |
us-gaap_CommonStockSharesOutstanding |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
| Name: |
us-gaap_NetIncomeLoss |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionAmount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a-c)
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32157-110900
| Name: |
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E
| Name: |
us-gaap_StockholdersEquity |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- Details
| Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
v3.3.1.900
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
|
12 Months Ended |
Oct. 31, 2015 |
Oct. 31, 2014 |
| CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
| Net loss attributable to ABMT common stockholders |
$ (862,854)
|
$ (827,756)
|
| Adjustments to reconcile net loss to cash used in operating activities: |
|
|
| Depreciation |
30,451
|
26,640
|
| Imputed interest |
21,164
|
$ 20,079
|
| Decrease (increase) in: |
|
|
| Inventories |
(2,825)
|
|
| Other receivables and prepaid expenses |
89
|
$ 2,270
|
| (Decrease) increase in: |
|
|
| Other payables and accrued expenses |
(6,418)
|
46,346
|
| Net cash used in operating activities |
(820,393)
|
(732,421)
|
| CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
| Purchase of property and equipment |
(32,311)
|
(8,793)
|
| (Increase) decrease in deposit for purchase of property and equipment |
15,899
|
(15,009)
|
| Net cash used in investing activities |
(16,412)
|
(23,802)
|
| CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
| Due to a stockholder |
102,959
|
109,253
|
| Due to directors |
50,376
|
(51,460)
|
| Due to related parties |
648,640
|
724,435
|
| Net cash provided by financing activities |
801,975
|
782,228
|
| EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS |
(1,220)
|
(31)
|
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS |
(36,050)
|
25,974
|
| CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR |
74,354
|
48,380
|
| CASH AND CASH EQUIVALENTS AT END OF YEAR |
$ 38,304
|
$ 74,354
|
| X |
- References
+ Details
| Name: |
us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- References
+ Details
| Name: |
us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- References
+ Details
| Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
| Name: |
us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
| Name: |
us-gaap_Depreciation |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionAmount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
| Name: |
us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
| Name: |
us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
| Name: |
us-gaap_IncreaseDecreaseInInventories |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- References
+ Details
| Name: |
us-gaap_IncreaseDecreaseInOperatingAssetsAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- References
+ Details
| Name: |
us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
| Name: |
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionThe net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
| Name: |
us-gaap_IncreaseDecreaseInRestrictedCash |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
| Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
| Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
| Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- References
+ Details
| Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
| Name: |
us-gaap_NetIncomeLoss |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
| Name: |
us-gaap_PaidInKindInterest |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
| Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionThe cash inflow from a borrowing not otherwise defined in the taxonomy having initial term of repayment within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
| Name: |
us-gaap_ProceedsFromOtherShortTermDebt |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionThe net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3095-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3098-108585
| Name: |
us-gaap_ProceedsFromPaymentsForOtherFinancingActivities |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
v3.3.1.900
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Accounting Policies [Abstract] |
|
| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION |
| 1. | SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION |
Advanced
Biomedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was
incorporated in Nevada on September 12, 2006.
Shenzhen
Changhua Biomedical Engineering Co., Ltd. (“Shenzhen Changhua”) was incorporated in the People’s Republic of
China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen
Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture
and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The
Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market
its products commercially pending the approval from the China Food and Drug Administration (“CFDA”, formerly known
as “SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting
Standards Codification (“ASC”) Topic 915, “Development Stage Entities”, is considered a Development Stage
Company.
Masterise
Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on 31 May, 2007 as an investment holding
company. Masterise is owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder and 37% by a third party
corporation.
On
January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen
Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February
25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as
a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated
financial statements as if the transactions had occurred retroactively.
On
December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of
Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest
in Masterise.
Concurrently,
on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate
Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder
sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250
shares to the stockholders of Masterise.
On
consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became a 80.7% stockholder
of ABMT.
On
March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.
The
merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the
accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have
been prepared as if the re-organization had occurred retroactively.
Accordingly,
these financial statements include the following:
| (1) | The
balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical
cost. |
| (2) | The
statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree
from the date of the transaction. |
ABMT,
Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).
| (B) | Principles
of consolidation |
The
accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise
and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’
30% proportionate share of the results of Shenzhen Changhua.
All
significant inter-company balances and transactions have been eliminated in consolidation.
The
preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires
management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.
| (D) | Cash
and cash equivalents |
For
purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a
maturity of less than three months. As of October 31, 2015 and 2014, all the cash and cash equivalents were denominated in United
States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with
banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC
are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control
restrictions imposed by the PRC government.
Inventories
are stated at the lower of cost, computed using the first-in, first-out method, or market, which represents selling price less
cost to sell. If the cost of the inventories exceeds their market value, provisions are made currently for the difference between
the cost and the market value.
| (F) | Property
and equipment |
Property
and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are
capitalized and expenditures for maintenance and repairs are charged to expense as incurred.
Depreciation
is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful
lives of the assets are 5 years.
The
Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Impairment or Disposal
of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For
purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to
recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which
are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2015 and 2014, the Company
has not recognized any allowances for impairment.
| (H) | Fair
value of financial instruments |
FASB
Codification Topic 825(ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures
regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables
and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term
nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest
or credit risks arising from these financial statements.
The
Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25,
deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax
rates is recognized as income in the period included the enactment date.
We
assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the
facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50%
likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized
upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions
where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial
statements.
| (J) | Research
and development |
Research
and development costs related to both present and future products are expensed as incurred. Total expenditure on research and
development charged to general and administrative expenses for the years ended October 31, 2015 and 2014 were $60,202 and $47,700
respectively.
| (K) | Foreign
currency translation |
The
reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in
their functional currencies of US$, HK$ and RMB respectively.
Foreign
currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates
of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at
the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing
at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.
The
financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated
into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective
balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the
transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences
are recorded within equity.
The
exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as
follows:
| |
|
October
31, 2015 |
|
October
31, 2014 |
| Balance sheet items, except for share
capital, additional paid-in capital and accumulated deficits, as of year end |
|
US$1=HK$7.7496=RMB6.3180 |
|
US$1=HK$7.7551=RMB6.1124 |
| |
|
|
|
|
Amounts
included in the statements of operations and cash flows for the year |
|
US$1=HK$7.7530=RMB6.2425 |
|
US$1=HK$7.7543=RMB6.1498 |
The
translation gain recorded for the years ended October 31, 2015 and 2014 were $118,739 and $3,586 respectively.
No
presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government
regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such
translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.
The
value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in China’s political
and economic conditions. Any significant revaluation of RMB may materially affect the Company’s financial condition in terms
of US$ reporting.
| (L) | Other
comprehensive loss |
The
foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$
is reported as other comprehensive gain or loss in the statements of operations and stockholders’ deficit. Other comprehensive
gain for the years ended October 31, 2015 and 2014 were $118,739 and $3,586 respectively.
Basic
loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding
during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to
include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional
shares were diluted. There are no potentially dilutive securities as at October 31, 2015 and October 31, 2014.
The
Company operates in only one segment, thereafter segment disclosure is not presented.
| (O) | Recent
Accounting Pronouncements |
In
August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern
(Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally
accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing
financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under
this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes
imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30,
Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent,
there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern.
In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the
amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events.
The amendments in this Accounting Standards Update are effective for the annual period ending after December 15, 2016, and for
annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations
in this ASU, however, at the current period, management does not believe that it has met conditions which would subject these
financial statements for additional disclosure.
|
| X |
- References
+ Details
| Name: |
us-gaap_AccountingPoliciesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.
| Name: |
us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
INVENTORIES
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Inventory Disclosure [Abstract] |
|
| INVENTORIES |
Inventories
as at October 31, 2015 and 2014 consisted of the followings:
| | |
October 31, | |
| | |
2015 | | |
2014 | |
| | |
| | |
| |
| Testing reagents | |
$ | 2,633 | | |
$ | — | |
| Packing materials | |
| 158 | | |
| — | |
| | |
$ | 2,791 | | |
$ | — | |
|
| X |
- References
+ Details
| Name: |
us-gaap_InventoryDisclosureAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a, b, c
-Article 5
| Name: |
us-gaap_InventoryDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
PROPERTY AND EQUIPMENT
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Property, Plant and Equipment [Abstract] |
|
| PROPERTY AND EQUIPMENT |
The
following is a summary of property and equipment at October 31, 2015 and 2014:
| | |
October 31, | |
| | |
2015 | | |
2014 | |
| | |
| | |
| |
| Plant and machinery | |
$ | 294,378 | | |
$ | 272,214 | |
| Motor vehicles | |
| 43,637 | | |
| 45,105 | |
| Office equipment | |
| 34,527 | | |
| 34,523 | |
| Computer software | |
| 5,017 | | |
| 5,017 | |
| Office improvements | |
| 127,162 | | |
| 131,439 | |
| Construction in progress | |
| | | |
| | |
| | |
| 504,721 | | |
| 488,298 | |
| Less: accumulated depreciation | |
| 398,102 | | |
| 380,044 | |
| | |
| | | |
| | |
| Property and equipment, net | |
$ | 106,619 | | |
$ | 108,254 | |
Depreciation
expense for the year ended October 31, 2015 and 2014 was $30,451 and $26,640 respectively.
|
| X |
- References
+ Details
| Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13-14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
| Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
OTHER PAYABLES AND ACCRUED EXPENSES
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Payables and Accruals [Abstract] |
|
| OTHER PAYABLES AND ACCRUED EXPENSES |
| 4. | OTHER
PAYABLES AND ACCRUED EXPENSES |
Other
payables and accrued expenses at October 31, 2015 and 2014 consisted of the following:
| | |
| | |
| |
| | |
October 31, | |
| | |
2015 | | |
2014 | |
| | |
| | |
| |
| Other payables | |
$ | 40 | | |
$ | 929 | |
| Accrued expenses | |
| 97,001 | | |
| 104,842 | |
| | |
$ | 97,041 | | |
$ | 105,771 | |
|
| X |
- DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- References
+ Details
| Name: |
us-gaap_PayablesAndAccrualsAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
RELATED PARTY TRANSACTIONS
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Related Party Transactions [Abstract] |
|
| RELATED PARTY TRANSACTIONS |
| 5. | RELATED
PARTY TRANSACTIONS |
As
of October 31, 2015 and 2014, the Company owed $562,187 and $459,131 respectively to Titan Technology Development Limited, a stockholder.
As
of October 31, 2015 and 2014, advances from related parties were as follows:
| | |
October 31, | |
| | |
2015 | | |
2014 | |
| | |
| | |
| |
| Chi Fung Yu | |
$ | 1,807,103 | | |
$ | 1,618,333 | |
| Que Feng | |
| 33,133 | | |
| — | |
| Chen Tie Jun | |
| 1,660,763 | | |
| 1,370,405 | |
| Shenzhen Hygeian Medical Device Co., Ltd. | |
| 27,229 | | |
| — | |
| Amount due to related parties | |
$ | 3,528,228 | | |
$ | 2,988,738 | |
Advances
from a stockholder and related parties are unsecured, repayable on demand and bearing interest at 7% per annum. Interest expenses
on advances from a stockholder and the related parties accrued for the years ended October 31, 2015 and 2014 were as follows:
| | |
October 31, | |
| | |
2015 | | |
2014 | |
| | |
| | |
| |
| Titan Technology Development Limited, a stockholder | |
$ | 31,615 | | |
$ | 26,081 | |
| Related parties: | |
| | | |
| | |
| Que Feng | |
| 1,495 | | |
| — | |
| Chi Fung Yu | |
| 99,978 | | |
| 87,351 | |
| Chen Tie Jun | |
| 87,089 | | |
| 67,961 | |
| Shenzhen Hygeian Medical Device Co., Ltd. | |
| 114 | | |
| — | |
| Interest expenses to a stockholder and related parties | |
$ | 220,291 | | |
$ | 181,393 | |
As
of October 31, 2015 and 2014, advances from directors were as follows:
| | |
October 31, | |
| | |
2015 | | |
2014 | |
| | |
| | |
| |
| Hui Wang | |
$ | 417,966 | | |
$ | 382,280 | |
| Chiming Yu | |
| 21,897 | | |
| 20,230 | |
| Amount due to directors | |
$ | 439,863 | | |
$ | 402,510 | |
Advances
from directors were unsecured, repayable on demand and interest free. Imputed interests on the amounts owed to Hui Wang, a director,
were $21,164 and $20,079 for the years ended October 31, 2015, and 2014 respectively.
|
| X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A
| Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
STOCKHOLDERS DEFICIENCY
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Equity [Abstract] |
|
| STOCKHOLDERS DEFICIENCY |
| 6. | STOCKHOLDERS’
DEFICIENCY |
On
December 8, 2011, the Company issued 100,000 shares of restricted common stock at $0.2 to Dr. John Lynch, the Company’s
chief officer of dental technologies, for services for a term of twelve months. The shares were valued at the closing price on
the date of grant yielding an aggregate fair value of $20,000, fully recognised in prior years as consultancy fees included in
general and administrative expenses.
On
28 October 2013, the Company issued 150,000 shares of restricted common stock as directors’ services compensation for past
services to each of Mr. Chi Ming Yu and Kai Gui, directors of the Company. The shares were valued at the closing price of $0.71
per share on the date of grant, yielding an aggregate fair value of $213,000.
|
| X |
- References
+ Details
| Name: |
us-gaap_EquityAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656
Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494
Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644
Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E
Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C
| Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
COMMITMENTS AND CONTINGENCIES
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Commitments and Contingencies Disclosure [Abstract] |
|
| COMMITMENTS AND CONTINGENCIES |
| 7. | COMMITMENTS
AND CONTINGENCIES |
The
full time employees of the Company are entitled to employee benefits including medical care, welfare subsidies, unemployment insurance
and pension benefits through a Chinese government mandated multi-employer defined contribution plan. The Company is required to
accrue for these benefits based on certain percentages of the employees’ salaries and make contributions to the plans out
of the amounts accrued for medical and pension benefits. The total provisions and contributions made for such employee benefits
was $75,813 and $74,189 for the years ended October 31, 2015 and 2014 respectively. The Chinese government is responsible for
the medical benefits and the pension liability to be paid to these employees.
The
Company leased from third parties office space, a staff canteen and an apartment for a director at monthly rent prevailing at
October 31, 2015 of $2,060, $135 and $1,266 (2014: $2,348, Nil and $1,309) respectively. All of these operating leases expired
on July 20, 2015, Jul 1, 2015 and June 30, 2014 respectively. The Company continues to lease these premises at same monthly rent
pending a formal renewal of these leases.
The
Company also leases five apartments (2014: eight apartments and a staff canteen) for staff under two operating leases (2014: three
leases) from third parties at monthly rental totaling $475 (2014: $965), both of which will expire in July 2015.
As
of October 31, 2015, the Company had outstanding commitments with respect to the above operating leases, which are due as follows:
| | | |
| | |
| 2016 | | |
| 4,856 | |
| 2017 | | |
| — | |
| Total | | |
$ | 4,856 | |
The
Company has no outstanding commitments contracted for, net of deposit paid, in respect of acquisitions of plant and machineries
as of October 31, 2015 (2014: $16,237).
|
| X |
- References
+ Details
| Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe entire disclosure for commitments and contingencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308
| Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
INCOME TAX
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Income Tax Disclosure [Abstract] |
|
| INCOME TAX |
ABMT was incorporated in the United States and has incurred net operating loss for income tax purposes for 2015 and 2014. ABMT has net operating loss carry forwards for income taxes amounting to approximately $1,612,970 and $1,512,723 as of October 31, 2015 and 2014 respectively which may be available to reduce future years’ taxable income. These carry forwards, will expire, if not utilized, commencing in 2029. Management believes that the realization of the benefits from these losses appears uncertain due to the Company’s limited operating history and continuing losses. Accordingly, a full, deferred tax asset valuation allowance has been provided and no deferred tax asset valuation allowance has been provided and no deferred tax asset benefit has been recorded. The valuation allowance at October 31, 2015 and 2014 was $548,410 and $514,326 respectively. The net change in the valuation allowance for 2015 was an increase of $34,084.
Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.
Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been 25%. No income tax expense has been provided by Shenzhen Changhua as it has incurred losses. The losses cannot be carried forward as Shenzhen Changhua has not yet commenced operation.
|
| X |
- DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
| Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
CONCENTRATIONS AND RISKS
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Risks and Uncertainties [Abstract] |
|
| CONCENTRATIONS AND RISKS |
| 9. | CONCENTRATIONS
AND RISKS |
As
at October 31, 2015, 94% and 6% of the Company’s assets were located in the P.R.C. and the United States respectively.
As
at October 31, 2014, 91% and 9% of the Company’s assets were located in the P.R.C. and the United States respectively.
|
| X |
- DefinitionThe entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6327-108592
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6442-108592
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611
| Name: |
us-gaap_ConcentrationRiskDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- References
+ Details
| Name: |
us-gaap_RisksAndUncertaintiesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
GOING CONCERN
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Going Concern |
|
| GOING CONCERN |
As
reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $6,262,961 as of October
31, 2015 that includes a net loss of $862,854 for the year ended October 31, 2015. The Company’s total current liabilities
exceed its total current assets by $4,568,106 and the Company used cash in operations of $820,393. These factors raise substantial
doubt about its ability to continue as a going concern. In view of the matters described above, recoverability of a major portion
of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which
in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and succeed in its future
operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as
a going concern.
To
continue as a going concern, the Company is actively pursuing additional funding and strategic partners to enable it to implement
its business plan. Management believes that these actions, if successful, will allow the Company to continue its operations through
the next fiscal year.
|
| X |
- References
+ Details
| Name: |
abtbi_GoingConcernAbstract |
| Namespace Prefix: |
abtbi_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51888302&loc=SL51888449-203568
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51888302&loc=SL51888443-203568
| Name: |
us-gaap_SubstantialDoubtAboutGoingConcernTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
SUBSEQUENT EVENT
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Subsequent Events [Abstract] |
|
| SUBSEQUENT EVENT |
The
Company has evaluated the existence of significant events subsequent to the balance sheet date through the date the financial
statements were issued and has determined that there were no subsequent events or transactions which would require recognition
or disclosure in the financial statements other than stated below:
On
[13 November 2015], the Company has entered into a Debt Conversion Agreement with a stockholder to convert $500,000 of the accrued
interest, payable to the Company’s the stockholder and its shareholders, into 10,000,000 shares (“The Conversion Shares”)
of common stock at a conversion price of $0.05 per share. Should the Conversion Shares have been issued as at October 31, 2015,
the loss per share for the year ended October 31, 2015 would be US$0.01.
|
| X |
- References
+ Details
| Name: |
us-gaap_SubsequentEventsAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
| Name: |
us-gaap_SubsequentEventsTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies)
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Accounting Policies [Abstract] |
|
| Principles of consolidation |
| (B) | Principles
of consolidation |
The
accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise
and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’
30% proportionate share of the results of Shenzhen Changhua.
All
significant inter-company balances and transactions have been eliminated in consolidation.
|
| Use of estimates |
The
preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires
management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.
|
| Cash and cash equivalents |
| (D) | Cash
and cash equivalents |
For
purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a
maturity of less than three months. As of October 31, 2015 and 2014, all the cash and cash equivalents were denominated in United
States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with
banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC
are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control
restrictions imposed by the PRC government.
|
| Inventories |
Inventories
are stated at the lower of cost, computed using the first-in, first-out method, or market, which represents selling price less
cost to sell. If the cost of the inventories exceeds their market value, provisions are made currently for the difference between
the cost and the market value.
|
| Property and equipment |
| (F) | Property
and equipment |
Property
and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are
capitalized and expenditures for maintenance and repairs are charged to expense as incurred.
Depreciation
is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful
lives of the assets are 5 years.
|
| Long-lived assets |
The
Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Impairment or Disposal
of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For
purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to
recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which
are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2015 and 2014, the Company
has not recognized any allowances for impairment.
|
| Fair value of financial instruments |
| (H) | Fair
value of financial instruments |
FASB
Codification Topic 825(ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures
regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables
and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term
nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest
or credit risks arising from these financial statements.
|
| Income taxes |
The
Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25,
deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax
rates is recognized as income in the period included the enactment date.
We
assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the
facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50%
likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized
upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions
where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial
statements.
|
| Research and development |
| (J) | Research
and development |
Research
and development costs related to both present and future products are expensed as incurred. Total expenditure on research and
development charged to general and administrative expenses for the years ended October 31, 2015 and 2014 were $60,202 and $47,700
respectively.
|
| Foreign currency translation |
| (K) | Foreign
currency translation |
The
reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in
their functional currencies of US$, HK$ and RMB respectively.
Foreign
currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates
of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at
the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing
at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.
The
financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated
into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective
balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the
transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences
are recorded within equity.
The
exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as
follows:
| |
|
October
31, 2015 |
|
October
31, 2014 |
| Balance sheet items, except for share
capital, additional paid-in capital and accumulated deficits, as of year end |
|
US$1=HK$7.7496=RMB6.3180 |
|
US$1=HK$7.7551=RMB6.1124 |
| |
|
|
|
|
Amounts
included in the statements of operations and cash flows for the year |
|
US$1=HK$7.7530=RMB6.2425 |
|
US$1=HK$7.7543=RMB6.1498 |
The
translation gain recorded for the years ended October 31, 2015 and 2014 were $118,739 and $3,586 respectively.
No
presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government
regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such
translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.
The
value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in China’s political
and economic conditions. Any significant revaluation of RMB may materially affect the Company’s financial condition in terms
of US$ reporting.
|
| Other comprehensive loss |
| (L) | Other
comprehensive loss |
The
foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$
is reported as other comprehensive gain or loss in the statements of operations and stockholders’ deficit. Other comprehensive
gain for the years ended October 31, 2015 and 2014 were $118,739 and $3,586 respectively.
|
| Loss per share |
Basic
loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding
during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to
include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional
shares were diluted. There are no potentially dilutive securities as at October 31, 2015 and October 31, 2014.
|
| Segments |
The
Company operates in only one segment, thereafter segment disclosure is not presented.
|
| Recent Accounting Pronouncements |
| (O) | Recent
Accounting Pronouncements |
In
August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern
(Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally
accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing
financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under
this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes
imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30,
Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent,
there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern.
In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the
amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events.
The amendments in this Accounting Standards Update are effective for the annual period ending after December 15, 2016, and for
annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations
in this ASU, however, at the current period, management does not believe that it has met conditions which would subject these
financial statements for additional disclosure.
|
| X |
- References
+ Details
| Name: |
us-gaap_AccountingPoliciesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Financial Reporting Release (FRR)
-Number 203
-Paragraph 02-03
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5
| Name: |
us-gaap_CashAndCashEquivalentsPolicyTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for comprehensive income.
| Name: |
us-gaap_ComprehensiveIncomePolicyPolicyTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph k
-Article 1
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02, 03
-Article 3A
| Name: |
us-gaap_ConsolidationPolicyTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
| Name: |
us-gaap_EarningsPerSharePolicyTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13279-108611
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260
| Name: |
us-gaap_FairValueOfFinancialInstrumentsPolicy |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
| Name: |
us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=51717228&loc=d3e202-110218
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section CC
-Subsection 3
| Name: |
us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318
| Name: |
us-gaap_IncomeTaxPolicyTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Financial Reporting Release (FRR)
-Number 206
-Paragraph b
-Subparagraph i, ii
-Chapter 2
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a
-Article 5
| Name: |
us-gaap_InventoryPolicyTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
| Name: |
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_PropertyPlantAndEquipmentPolicyTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Research and Development
-URI http://asc.fasb.org/extlink&oid=6523717
| Name: |
us-gaap_ResearchAndDevelopmentExpensePolicy |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for segment reporting. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
| Name: |
us-gaap_SegmentReportingPolicyPolicyTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592
| Name: |
us-gaap_UseOfEstimates |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Tables)
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Accounting Policies [Abstract] |
|
| Schedule of exchange rates used in translation |
The
exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as
follows:
| |
|
October
31, 2015 |
|
October
31, 2014 |
| Balance sheet items, except for share
capital, additional paid-in capital and accumulated deficits, as of year end |
|
US$1=HK$7.7496=RMB6.3180 |
|
US$1=HK$7.7551=RMB6.1124 |
| |
|
|
|
|
Amounts
included in the statements of operations and cash flows for the year |
|
US$1=HK$7.7530=RMB6.2425 |
|
US$1=HK$7.7543=RMB6.1498 |
|
| X |
- DefinitionExchange rates used in translation
| Name: |
abtbi_ScheduleOfExchangeRatesUsedInTranslationTableTextBlock |
| Namespace Prefix: |
abtbi_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- References
+ Details
| Name: |
us-gaap_AccountingPoliciesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
| X |
- References
+ Details
| Name: |
us-gaap_InventoryDisclosureAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a, b, c
-Article 5
| Name: |
us-gaap_InventoryDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
PROPERTY AND EQUIPMENT (Tables)
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Property, Plant and Equipment [Abstract] |
|
| Schedule of property and equipment |
The
following is a summary of property and equipment at October 31, 2015 and 2014:
| | |
October 31, | |
| | |
2015 | | |
2014 | |
| | |
| | |
| |
| Plant and machinery | |
$ | 294,378 | | |
$ | 272,214 | |
| Motor vehicles | |
| 43,637 | | |
| 45,105 | |
| Office equipment | |
| 34,527 | | |
| 34,523 | |
| Computer software | |
| 5,017 | | |
| 5,017 | |
| Office improvements | |
| 127,162 | | |
| 131,439 | |
| Construction in progress | |
| | | |
| | |
| | |
| 504,721 | | |
| 488,298 | |
| Less: accumulated depreciation | |
| 398,102 | | |
| 380,044 | |
| | |
| | | |
| | |
| Property and equipment, net | |
$ | 106,619 | | |
$ | 108,254 | |
|
| X |
- References
+ Details
| Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph b
-Article 5
| Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
| X |
- References
+ Details
| Name: |
us-gaap_PayablesAndAccrualsAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
| Name: |
us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
RELATED PARTY TRANSACTIONS (Tables)
|
12 Months Ended |
Oct. 31, 2015 |
|---|
| Related Party Transactions [Abstract] |
|
| Schedules of related parties amounts |
As
of October 31, 2015 and 2014, advances from related parties were as follows:
| | |
October 31, | |
| | |
2015 | | |
2014 | |
| | |
| | |
| |
| Chi Fung Yu | |
$ | 1,807,103 | | |
$ | 1,618,333 | |
| Que Feng | |
| 33,133 | | |
| — | |
| Chen Tie Jun | |
| 1,660,763 | | |
| 1,370,405 | |
| Shenzhen Hygeian Medical Device Co., Ltd. | |
| 27,229 | | |
| — | |
| Amount due to related parties | |
$ | 3,528,228 | | |
$ | 2,988,738 | |
Advances
from a stockholder and related parties are unsecured, repayable on demand and bearing interest at 7% per annum. Interest expenses
on advances from a stockholder and the related parties accrued for the years ended October 31, 2015 and 2014 were as follows:
| | |
October 31, | |
| | |
2015 | | |
2014 | |
| | |
| | |
| |
| Titan Technology Development Limited, a stockholder | |
$ | 31,615 | | |
$ | 26,081 | |
| Related parties: | |
| | | |
| | |
| Que Feng | |
| 1,495 | | |
| — | |
| Chi Fung Yu | |
| 99,978 | | |
| 87,351 | |
| Chen Tie Jun | |
| 87,089 | | |
| 67,961 | |
| Shenzhen Hygeian Medical Device Co., Ltd. | |
| 114 | | |
| — | |
| Interest expenses to a stockholder and related parties | |
$ | 220,291 | | |
$ | 181,393 | |
As
of October 31, 2015 and 2014, advances from directors were as follows:
| | |
October 31, | |
| | |
2015 | | |
2014 | |
| | |
| | |
| |
| Hui Wang | |
$ | 417,966 | | |
$ | 382,280 | |
| Chiming Yu | |
| 21,897 | | |
| 20,230 | |
| Amount due to directors | |
$ | 439,863 | | |
$ | 402,510 | |
|
| X |
- DefinitionTabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
| Name: |
us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
| X |
- References
+ Details
| Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717
| Name: |
us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details Narrative) - USD ($)
|
|
|
|
|
12 Months Ended |
Dec. 31, 2008 |
Jan. 28, 2008 |
May. 31, 2007 |
Sep. 25, 2002 |
Oct. 31, 2015 |
| Ownership of subsidiaries |
|
|
|
|
70.00%
|
| Ownership by noncontrolling stockholders |
|
|
|
|
30.00%
|
| Estimated useful lives of property and equipment |
|
|
|
|
5 years
|
| Likelyhood that tax benefit sustained |
|
|
|
|
50.00%
|
| Masterise [Member] |
|
|
|
|
|
| Ownership interest - majority stockholder |
|
|
63.00%
|
|
|
| Ownership interest - minority stockholder |
|
|
37.00%
|
|
|
| Masterise [Member] | ABMT [Member] |
|
|
|
|
|
| Ownership acquired |
100.00%
|
|
|
|
|
| Stock issued in acquisition, shares |
50,000
|
|
|
|
|
| Masterise [Member] | Shenzhen Changhua [Member] |
|
|
|
|
|
| Payment for acquisition |
|
$ 64,100
|
|
|
|
| Ownership acquired |
|
70.00%
|
|
|
|
| Shenzhen Changhua [Member] |
|
|
|
|
|
| Registered capital |
|
|
|
$ 724,017
|
|
| Ownership interest - majority stockholder |
|
|
|
70.00%
|
|
| Ownership interest - minority stockholder |
|
|
|
30.00%
|
|
| Majority Shareholders [Member] | ABMT [Member] |
|
|
|
|
|
| Stock sold per Affiliate Agreement |
$ 5,000
|
|
|
|
|
| Stock sold per Affiliate Agreement, shares |
5,001,000
|
|
|
|
|
| Ownership after Affiliate Agreement |
80.70%
|
|
|
|
|
| Majority Shareholders [Member] | Masterise [Member] |
|
|
|
|
|
| Stock sold per Affiliate Agreement, shares |
4,438,250
|
|
|
|
|
| X |
- DefinitionPercentage likelyhood that tax benefit will be sustained.
| Name: |
abtbi_LikelyhoodThatTaxBenefitSustained |
| Namespace Prefix: |
abtbi_ |
| Data Type: |
num:percentItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463
| Name: |
us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:percentItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- DefinitionThe amount of total capital as defined in the regulations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 948
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 505
-Section 50
-Paragraph 1H
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35709795&loc=d3e65071-112826
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 505
-Section 50
-Paragraph 1H
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=35709795&loc=d3e65071-112826
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 948
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998
| Name: |
us-gaap_Capital |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionPercentage investment held by the managing member or general partner of the limited liability company (LLC) or limited partnership (LP). Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055
| Name: |
us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:percentItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe number of units or percentage investment held by one or more members or limited partners of the LLC or LP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055
| Name: |
us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:percentItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.
| Name: |
us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:percentItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- DefinitionThe parent entity's interest in net assets of the subsidiary, expressed as a percentage.
| Name: |
us-gaap_MinorityInterestOwnershipPercentageByParent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:percentItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- DefinitionThe cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
| Name: |
us-gaap_PaymentsToAcquireBusinessesGross |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
| Name: |
us-gaap_PropertyPlantAndEquipmentUsefulLife |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:durationItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCash received on stock transaction after deduction of issuance costs.
| Name: |
us-gaap_SaleOfStockConsiderationReceivedOnTransaction |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
| Name: |
us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionPercentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.
| Name: |
us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:percentItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28,29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
| Name: |
us-gaap_StockIssuedDuringPeriodSharesAcquisitions |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abtbi_MasteriseMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
dei_LegalEntityAxis=us-gaap_ParentCompanyMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
v3.3.1.900
| X |
- DefinitionForeign exchange rate used to translate amounts denominated in functional currency to reporting currency. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521
| Name: |
us-gaap_ForeignCurrencyExchangeRateTranslation1 |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:pureItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- Details
| Name: |
us-gaap_CurrencyAxis=currency_HKD |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_IncomeStatementLocationAxis=abtbi_IncomeStatementAndCashFLowsMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_CurrencyAxis=currency_CNY |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
v3.3.1.900
| X |
- References
+ Details
| Name: |
us-gaap_InventoryDisclosureAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
| Name: |
us-gaap_InventoryNet |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_InventoryRawMaterials |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Inventory
-URI http://asc.fasb.org/extlink&oid=6516093
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_OtherInventorySupplies |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
v3.3.1.900
PROPERTY AND EQUIPMENT (Details) - USD ($)
|
Oct. 31, 2015 |
Oct. 31, 2014 |
| Property and equipment |
$ 504,721
|
$ 488,298
|
| Less: accumulated depreciation |
398,102
|
380,044
|
| Property and equipment, net |
106,619
|
108,254
|
| Plant and Machinery [Member] |
|
|
| Property and equipment |
294,378
|
272,214
|
| Motor Vehicles [Member] |
|
|
| Property and equipment |
43,637
|
45,105
|
| Office Equipment [Member] |
|
|
| Property and equipment |
34,527
|
34,523
|
| Computer Software [Member] |
|
|
| Property and equipment |
5,017
|
5,017
|
| Office Improvements [Member] |
|
|
| Property and equipment |
$ 127,162
|
$ 131,439
|
| X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_PropertyPlantAndEquipmentGross |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph a
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 8
-Article 7
| Name: |
us-gaap_PropertyPlantAndEquipmentNet |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- Details
| Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
v3.3.1.900
| X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677
| Name: |
us-gaap_AccountsPayableOtherCurrent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
| Name: |
us-gaap_AccruedLiabilitiesCurrent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionAggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
| Name: |
us-gaap_OtherLiabilitiesCurrent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- References
+ Details
| Name: |
us-gaap_PayablesAndAccrualsAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
v3.3.1.900
| X |
- DefinitionAmounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 12
-Subparagraph a(1)
-Article 6
| Name: |
us-gaap_DueToOfficersOrStockholdersCurrent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
v3.3.1.900
RELATED PARTY TRANSACTIONS (Details) - USD ($)
|
Oct. 31, 2015 |
Oct. 31, 2014 |
| Due to related parties |
$ 3,528,228
|
$ 2,988,738
|
| Chi Fung Yu [Member] |
|
|
| Due to related parties |
1,807,103
|
1,618,333
|
| Que Feng [Member] |
|
|
| Due to related parties |
33,133
|
|
| Chen Tie Jun [Member] |
|
|
| Due to related parties |
1,660,763
|
$ 1,370,405
|
| Shenshen Hygeian Medical Device Co.Ltd [Member] |
|
|
| Due to related parties |
$ 27,229
|
|
v3.3.1.900
RELATED PARTY TRANSACTIONS (Details 1) - USD ($)
|
12 Months Ended |
Oct. 31, 2015 |
Oct. 31, 2014 |
| Interest expenses to a stockholder and related parties |
$ 220,291
|
$ 181,393
|
| Titan Technology Development Ltd - Stockholder |
|
|
| Interest expenses to a stockholder and related parties |
31,615
|
26,081
|
| Que Feng [Member] |
|
|
| Interest expenses to a stockholder and related parties |
1,495
|
|
| Chi Fung Yu [Member] |
|
|
| Interest expenses to a stockholder and related parties |
99,978
|
87,351
|
| Chen Tie Jun [Member] |
|
|
| Interest expenses to a stockholder and related parties |
87,089
|
$ 67,691
|
| Shenshen Hygeian Medical Device Co.Ltd [Member] |
|
|
| Interest expenses to a stockholder and related parties |
$ 114
|
|
v3.3.1.900
| X |
- DefinitionCarrying amount as of the balance sheet date of obligations due stockholders. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
| Name: |
abtbi_DueToDirectors |
| Namespace Prefix: |
abtbi_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
v3.3.1.900
| X |
- DefinitionPer share or per unit amount of equity securities issued.
| Name: |
us-gaap_SharesIssuedPricePerShare |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:perShareItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
| Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
| Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
v3.3.1.900
COMMITMENTS AND CONTINGENCIES (Details Narrative)
|
1 Months Ended |
12 Months Ended |
|
Oct. 31, 2015
USD ($)
|
Oct. 31, 2014
USD ($)
|
Oct. 31, 2015
USD ($)
|
Oct. 31, 2014
USD ($)
|
| Contributions under defined contribution plan |
|
|
$ 75,813
|
$ 74,189
|
| Number of leases |
2
|
3
|
2
|
3
|
| Number of apartments |
5
|
8
|
5
|
8
|
| Plant and machineries commitments |
|
$ 16,237
|
|
$ 16,237
|
| Office Space [Member] |
|
|
|
|
| Rent expense |
$ 2,060
|
2,348
|
|
|
| Staff Canteen [Member] |
|
|
|
|
| Rent expense |
135
|
0
|
|
|
| Staff Apartment [Member] |
|
|
|
|
| Rent expense |
1,266
|
1,390
|
|
|
| Staff Apartments and Canteen [Member] |
|
|
|
|
| Rent expense |
$ 475
|
$ 965
|
|
|
| X |
- DefinitionThe number of apartments in a real estate property leased as of the balance sheet date.
| Name: |
abtbi_NumberOfApartments |
| Namespace Prefix: |
abtbi_ |
| Data Type: |
xbrli:integerItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- DefinitionThe number of operating leases as of the balance sheet date.
| Name: |
abtbi_NumberOfLeases |
| Namespace Prefix: |
abtbi_ |
| Data Type: |
xbrli:integerItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- DefinitionAmount of contributions made to multiemployer plans by the employer. A multiemployer plan is a pension or postretirement benefit plan to which two or more unrelated employers contribute where assets contributed by one participating employer may be used to provide benefits to employees of other participating employers. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 80
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=49170332&loc=SL14450702-114947
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 80
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=49170332&loc=SL14450691-114947
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 80
-Section 50
-Paragraph 5
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=49170332&loc=SL14450657-114947
| Name: |
us-gaap_MultiemployerPlanPeriodContributions |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionThis element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7661868&loc=d3e34039-112682
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697
| Name: |
us-gaap_OperatingLeasesRentExpenseMinimumRentals |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- DefinitionMinimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.
| Name: |
us-gaap_OtherCommitment |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- Details
| Name: |
us-gaap_LeaseArrangementTypeAxis=abtbi_LeaseArrangementMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_LeaseArrangementTypeAxis=abtbi_LeaseArrangement2Member |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_LeaseArrangementTypeAxis=abtbi_LeaseArrangement3Member |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_LeaseArrangementTypeAxis=abtbi_LeaseArrangement1Member |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
v3.3.1.900
| X |
- References
+ Details
| Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAmount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717
| Name: |
us-gaap_OperatingLeasesFutureMinimumPaymentsDue |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717
| Name: |
us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
v3.3.1.900
| X |
- DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
| Name: |
us-gaap_DeferredTaxAssetsValuationAllowance |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319
| Name: |
us-gaap_OperatingLossCarryforwards |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
instant |
|
| X |
- DefinitionAmount of increase (decrease) in the valuation allowance for a specified deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32123-109318
| Name: |
us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
v3.3.1.900
| X |
- DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611
| Name: |
us-gaap_ConcentrationRiskPercentage1 |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:percentItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
us-gaap_ConcentrationRiskByTypeAxis=us-gaap_AsiaMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AssetsTotalMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_ConcentrationRiskByTypeAxis=us-gaap_NorthAmericaMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
v3.3.1.900
| X |
- References
+ Details
| Name: |
abtbi_GoingConcernDetailsNarrativeAbstract |
| Namespace Prefix: |
abtbi_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
abtbi_LiabilitiesExceedingCurrentAssets |
| Namespace Prefix: |
abtbi_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
v3.3.1.900
| X |
- DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
| Name: |
us-gaap_DebtConversionConvertedInstrumentSharesIssued1 |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
| Name: |
us-gaap_DebtConversionOriginalDebtAmount1 |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870
| Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:perShareItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9
| Name: |
us-gaap_EarningsPerShareBasic |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:perShareItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
Advanced BioMedical Tech... (CE) (USOTC:ABMT)
Historical Stock Chart
From Feb 2025 to Mar 2025
Advanced BioMedical Tech... (CE) (USOTC:ABMT)
Historical Stock Chart
From Mar 2024 to Mar 2025
